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Our understanding of the spectral nature of the neglected tropical disease 
leishmaniasis, and of host-parasite interactions in general, remains incomplete. In this 
work, we used high throughput RNA-sequencing (RNA-seq) to analyze human host and 
Leishmania gene expression in cutaneous leishmaniasis patients. Skin biopsies were 
taken from a total of 25 localized cutaneous leishmaniasis (LCL), 6 diffuse cutaneous 
leishmaniasis (DCL), and 10 healthy patients. LCL separated into groups that lacked 
detectable parasite transcripts in lesions (PTNeg) and a group in which parasite transcripts 
were readily detected (PTPos). These groups exhibited substantial differences in host 
responses to infection, including B lymphocyte presence, B and T cell activation, and 
immunoglobulin production. Analysis of DCL lesions revealed distinct differences in 
host responses relative to LCL, including atypical B lymphocyte accumulation, 
diminished cytotoxic T lymphocyte responses, and an altered macrophage activation 
state. Surprisingly, neither localized nor diffuse forms of the disease could be correlated 





mouse models of L. major susceptibility. The presence of low levels of parasite 
transcripts in the majority of LCL patients made it difficult to obtain a comprehensive 
analysis of the parasite transcriptome in LCL. However, high levels of parasite transcripts 
in DCL afforded a unique opportunity to examine parasite gene expression in this 
disease. Despite differences in age, gender, and illness duration, there was a remarkable 
uniformity in parasite gene expression in all 6 DCL patients. We identified transcripts 
that were highly expressed by all 6 DCL patients, and then curated a subset of conserved 
genes highly expressed in multiple Leishmania species. These subsets of genes emerge as 
targets for further research on host-pathogen interactions and a better understanding of 
Leishmania infection.. In summary, RNA-seq allowed us to fully examine host and 
parasite transcriptomes, characterize host responses in localized and diffuse cutaneous 
leishmaniasis lesions, and determine factors that define the variations in disease 
manifestation. New approaches to modify host immune responses in this disease and new 
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Chapter 1: Introduction 
1.1 Innate Immunity 
 Innate immunity is comprised of physical barriers, humoral factors, and specific 
immune cells that developed over millions of years. It is most often described as the first 
line of defense used by organisms in the presence of infection, injury, or damage. At its 
most basic level, human innate immunity employs physical barriers like the skin and 
mucosal surfaces to stop or trap debris and microbes, preventing contact with epithelial 
layers and sensitive areas that require protection in order to maintain homeostasis. As 
immunity continued to evolve, innate responses developed various non-specific factors to 
immediately respond to the presence of foreign material. For example, antimicrobial 
peptides (AMPs) recognize and kill harmful microbes residing on the skin, in the gut, and 
in bodily fluids through the recognition of differences between human and microbial lipid 
layers. Coagulation factors, another non-specific development by the immune system, 
prevent microbial access to injured tissue and quickly arrest bleeding after vascular 
injury. The even more complicated complement system in the blood can bind foreign 
pathogens, leading to uptake by professional phagocytes, production of inflammatory 
signals, and downstream formation of membrane attack complexes. This occurs through a 
cascade of convertase formation and protease activity involving many different 
complement proteins working in consort. The evolution and development of these aspects 
of innate immunity help form a complex system that prevents and responds to infection, 
injury, and tissue damage. 
 Within the construct of innate immunity, cells employ receptors that enable the 







work by Le Maître and Hoffman first uncovered toll-like receptors (TLRs), 
demonstrating the susceptibility of the fruitfly to fungal infection when lacking the TLR1 
gene (1). We now know that this and many other pattern recognition receptors (PRRs) (2) 
exist: toll-like receptors (TLRs), retinoid acid-inducible gene I (RIG-I)-like receptors 
(RLRs), AIM2-like receptors (ALRs), and nucleotide-binding oligomerization domain 
(NOD)-like receptors (NLRs). These all recognize pathogen associated molecular 
patterns (PAMPs) or damage associated molecular patterns (DAMPs), inducing quick 
and effective neutralization of pathogens or damaging circumstances. Downstream 
signaling cascades initiated by PRR ligation typically lead to cellular production of 
cytokines and chemokines and also initiate downstream pathways involved in pathogen 
uptake and killing.  
The signaling pathways downstream of PAMP and DAMP receptor ligation of 
PRRs swiftly induce inflammatory responses and contribute to the initiation of adaptive 
immunity (3). In a well-studied example, bacterial lipopolysaccharide (LPS), signaling 
through TLR4, causes the rapid production of inflammatory cytokines such as tumor 
necrosis factor (TNF) by macrophages. This production is due to the activation of basal 
state positioning of RNA polymerase II on the gene’s promoter (4). PRR ligation also 
leads to stabilization of major histocompatibility complex (MHC) antigen presentation 
and upregulation of costimulatory molecules necessary for T cell activation (discussed 
later). The early inflammatory response induced by PRRs consists of downstream 
cytokine and chemokine production while simultaneously preparing contributions to 







It is vital that homeostasis is restored after initial inflammatory responses via 
immunoregulatory pathways to prevent immune-driven pathology. Endogenous 
regulators such as adenosine, prostaglandin, resolvins, and lipoxins can help to promote 
the resolution of inflammation (5). Adenosine triphosphate (ATP) is produced during 
inflammation as a result of metabolic switching and released from macrophages (6). 
Once outside the cell, ATP is catabolized to adenosine by the CD39 and CD73 
ectoenzymes (7, 8). Our lab has shown that adenosine then acts as a secondary signal that 
decreases production of TNF and inflammatory interleukin 12 (IL-12) while 
simultaneously increasing anti-inflammatory interleukin 10 (IL-10) production (9). 
Prostaglandins and prostanoids, signaling through G-protein coupled receptors (GPCRs), 
stimulate the release of cyclic adenosine monophosphate (cAMP). Coupling cAMP 
release with TLR signaling decreases macrophage production of inflammatory IL-12 and 
TNF while increasing IL-10 release (10, 11). Resolvins and lipoxins are also produced 
during inflammation and act as negative feedback to decrease inflammatory signaling. 
They also discourage further infiltration of polymorphonuclear cells and encourage 
uptake of dying or necrotic cells (5, 12). These endogenous regulators act through a 
variety of pathways toward the same goal of restoring homeostasis after inflammation. 
The immune system can also react to exogenous inhibition of inflammation. 
Glucocorticoids are one well-studied exogenous inhibitor of inflammation. Ligation of 
glucocorticoid receptors decreases inflammatory cytokine production, antigen 
presentation, and mRNA stability while increasing the phagocytosis of apoptotic cells. 
This occurs via downstream inhibition of nuclear factor kappa-B (NF-κB) nuclear 







glucocorticoids in treatments of MS, rheumatoid arthritis, psoriasis, and other 
autoimmune diseases (15). Other exogenous regulators of inflammation signal through 
specific receptors like CD47, CD200R, TREM2, TAM receptors, and 
phosphatidylcholine receptors in mucosal layers (5, 19). Whether to reestablish 
homeostasis or prevent initial activation, the signaling cascades initiated by exogenous 
mediators aim to subdue the inflammatory response and reduce the production of 
inflammatory cytokines and superoxides.  
Our knowledge of which cell types are most important to innate immunity 
continues to evolve. Macrophages, dendritic cells, neutrophils, and natural killer (NK) 
cells have always been considered part of innate immunity, contributing to removal and 
destruction of foreign material, rapid infiltration of damaged tissue, coordination of 
immune responses via cytokine and chemokine production, and targeted cell killing to 
eliminate infected cells. However, growing knowledge has also uncovered subsets of T 
and B lymphocytes that contribute to innate immunity through a restricted set of antigen 
receptors. In early immune responses, these cells can do much of the same processes as 
the aforementioned cells as well as produce a repertoire of natural antibodies (B cells). 
Research continues to uncover entire subgroups of lymphoid cells that contribute to 
innate immunity. The discovery of these so-called innate lymphoid cells (ILCs) have 
expanded our understanding of the complex innate immune system. 
Despite the complexities of innate immunity, pathogens have evolved numerous 
paths to avoid or manipulate innate immunity meant for pathogen killing or 
neutralization. Formation of capsules by bacteria prevents PRR access to bacterial 







protein kinase (MAPK) signaling to decrease inflammatory IL-12 production and 
promote anti-inflammatory IL-10 production (20). M. tuberculosis relies on an inhibition 
of inflammatory interferon-gamma (IFN-γ) and promotion of IL-10 production to survive 
and replicate in macrophages (21). Intestinal and urogenital bacteria such as 
Lactobacillus rhamnosus can also promote anti-inflammatory responses from 
macrophages. The commensal bacteria's secretome is able to induce granulocyte colony-
stimulating factor (G-CSF) production by macrophages, leading to activation of signal 
transducers and activators of transcription 3 (STAT3), c-Jun N-terminal kinase (JNK) 
inactivation, and inflammatory TNF suppression in LPS or E. coli-activated macrophages 
(22). As immune systems have evolved to defend against pathogens, so too have 
pathogens evolved to manipulate immune systems. 
1.2 Adaptive Immunity 
While innate immunity responds in a similar manner every time it encounters the 
same antigen or trigger, the adaptive immune system provides a learned, specific memory 
used to prevent reinfection by the same pathogen. The initiation of an adaptive immune 
response typically starts with antigen presenting cells (APCs) and professional 
phagocytes like dendritic cells and macrophages. These professional phagocytes engulf 
and kill pathogens, in the process breaking down peptides that are subsequently presented 
to T cells using MHCs. Presentation of peptide from exogenous sources in MHC II 
interacts with CD4+ T cells, while presentation of peptide from endogenous sources in 
MHC I interacts with CD8+ T cells. These interactions will lead to either T helper cell 
proliferation (CD4+) necessary for downstream B cell activation or CTL proliferation 







directs responses as well. Alongside MHC-peptide complex presentation to T cells, 
signaling via PRRs is needed to upregulate costimulatory molecules CD80 (B7.1) and 
CD86 (B7.2) that interact with CD28 on T cells, eliciting T cell activation. Without the 
presentation of antigenic peptide by APCs, adaptive immunity lacks the signals required 
for activation. 
T cells use the T cell receptor (TCR) to achieve diverse repertoires that recognize 
short peptides presented in MHC. The T cell receptor forms through DNA recombination 
during maturation and does not undergo further mutations after encountering antigen. 
Most T cell function is determined by the expression of either CD4 or CD8, forming T 
helper (Th) cells or cytotoxic T lymphocytes (CTL), respectively. Helper T cells play a 
prominent role in B cell activation, producing cytokines that will bias immune responses. 
These can be inflammatory (Th1), anti-inflammatory (Th2), or a mixture of the two. 
Cytotoxic responses are either inflammatory or cytolytic. Recent discoveries of numerous 
other T cell subsets have revealed regulatory T cells (Treg), γδ T cells, and NK T cells. 
Research continues to uncover new T lymphocyte functions, but some of the most basic 
include cytokine responses, immune regulation, targeted cell killing, and B cell 
activation.  
In B lymphocytes, diversity is also accomplished through a diverse repertoire of 
receptors created through DNA recombination events during cell maturation that enable 
each cell to recognize a specific antigen. Each B cell produces clonal B cell receptors 
(BCRs) unique to that cell that can bind antigen and send proliferative signals with the 
help of the CD79A/CD79B (Igα/Igβ) signaling proteins. The gene encoding for the BCR 







opsonization and uptake, neutralization, and killing. Exposure to antigens drives B cell 
proliferation and leads to somatic hypermutation and affinity maturation of BCRs and 
antibody to allow for stronger binding of antigen and more rapid future responses. After 
antigen recognition, B cells proliferate into plasma and memory cells, poised to produce 
large amounts of antibody, neutralize the current infection and produce robust immune 
memory for any subsequent encounters with the same antigen.  
During infection, B cells typically respond via T cell-dependent pathways. B cell 
receptors (IgM or IgD) may recognize surface or soluble antigen produced by pathogens. 
However, the recognition of antigen does not induce most B cell proliferation effectively 
without T cell help. This process occurs mainly through T cell production of cytokines 
and ligation of CD40 on B cells, inducing B cell proliferation and determining 
immunoglobulin isotype class switching, the irreversible DNA splicing of constant 
regions in the immunoglobulin sequence to produce IgG, IgA, or IgE. Determinants of 
most B cell proliferation and class switching events depend highly on the signals present 
in the microenvironment, cytokines, and signals from helper T cells.  
The isotype of immunoglobulin produced by each B cell directly influences B cell 
function. Production of IgM either on the surface or in a soluble pentameric form can 
occur in immature or mature B cells. The IgM isotype is the most effective isotype for 
complement activation. Production of IgA typically arises in or near mucosal membranes 
due to its ability to permeate mucosal surfaces and “neutralize” potential pathogens. The 
IgE isotype relates to allergic responses, binding to fragment crystallizable (Fc) epsilon-
receptors on mast cells. Subsequent binding of IgE to allergens en masse causes the 







role of specific IgGs varies. In humans, four types of IgG (IgG1, IgG2, IgG3, IgG4) 
differ in structure, their abilities to bind specific molecules (proteins, polysaccharides, 
allergens, complement C1q protein), and their affinity for various Fc receptors. While 
IgG1 and IgG3 usually induce strong effector reactions, IgG2 and IgG4 usually promote 
more subtle responses (23). The various functions of immunoglobulin isotypes drives B 
cell function throughout the entire human body.  
 While the complex nature of the adaptive immune response allows for highly 
specific and powerful responses to pathogenic invasion, many pathogens rely on 
avoidance or manipulation of the immune system for their survival (24). As a first level 
of defense, many bacterial pathogens avoid detection through the previously mentioned 
formation of capsules, preventing antibody or complement binding. Other pathogens use 
antigenic variation to avoid detection by B and T memory cells, altering surface proteins 
like the highly conserved bacterial LPS or more specific lipooligosaccharide (LOS) on 
Neisseria spp. (25). Trypanosomes, close relatives of the Leishmania genus, possess 
variant surface glycoproteins (VSGs) and replenish this dense protein coat to prevent 
antibody detection and complement activation (26). Probably the most well-known 
example of pathogenic evasion of immune memory is antigenic switching by the 
influenza virus. Slight changes in the genes coding for viral surface proteins are enough 
to avoid detection by memory antibody from previous flu infections.  
Evasion of immune responses is not the only way pathogens survive in host 
environments. We also know that pathogens manipulate adaptive immune responses by 
actively interfering with signaling cascades to promote favorable conditions for survival. 







decreasing inflammatory Th1/Th17 responses and promoting Th2 response environments 
(27). A toxin produced by Helicobacter pylori disrupts T cell proliferation by inhibiting 
IL-2 signaling (28). The Opa protein on Neisseria gonorrhoeae binds the host protein 
CEACAM1, dampening CD4 T cell activation and proliferation (29). Probably the most 
well-known example of adaptive immune modulation is used by human 
immunodeficiency virus (HIV) when the gp120 envelope glycoprotein expressed on the 
virion surface aides viral binding to and entry into CD4+ T cells (30–32). Pathogens are 
continuously finding ways to avoid and manipulate our adaptive immune system despite 
its complexity and diversity. 
1.3 Skin Immunity and Wound Healing 
 There are many cellular immune responses involved in skin immunity besides the 
structural aspect acting as a physical barrier. Within this construct, there are tissue-
resident cells that act as first-responders to pathogens or damage, recruiting and working 
in concert with infiltrating immune cells. Keratinocytes produce AMPs (antimicrobial 
peptides) in response to PRR ligation or cytokine signaling (33). Additionally, 
keratinocytes contribute substantially to early cytokine and chemokine production 
necessary for leukocyte recruitment (34). Various dendritic cell (DC) types like 
Langerhans cells also contribute to skin immune responses by promoting tolerance to 
natural skin flora (35). Research has also show that this specific subset of DCs is quite 
effective at suppressing immune responses by either inducing T cell deletion (36) or 
activating regulatory T cells (37). Other DC subtype functions include capturing dead 
cells and being the the first cells to process and present antigen (33). In Leishmania 







successful T cell activation (38). Recent discoveries of innate lymphoid cells (ILCs) in 
skin have suggested their contribution to inflammation and immune suppression, 
specifically by the ILC2 subtype characterized by GATA3, IL-4, and IL-13 expression 
(39). Lastly, tissue-resident T cells that do not leave the skin can either possess the 
common αβ TCR or the less diverse and less common γδ TCR. Particularly after previous 
infection, αβ T cells remain in the skin to provide immune memory and prevent future 
infection. As for γδ T cells, their function appears to lie in the realm of monitoring 
epidermal stress and contributing to wound healing (40). 
 Immune cells not only protect against pathogen invasion and damage, but 
contribute to the resolution of damage through wound healing. This process occurs in 
three stages: inflammation, proliferation, and remodeling (41). During the beginning of 
inflammation, infiltrating neutrophils function to both prevent pathogenic infection and 
activate keratinocytes, fibroblasts, and other immune cells (42–44). Infiltrating 
macrophages produce growth factors, matrix metalloproteinases (MMPs), VEGF, and 
TGFβ, all of which promote re-epithelialization, fibroblast growth, angiogenesis, and 
extracellular matrix remodeling (45–47). In Leishmania infection, constitutive expression 
of inflammatory and cytotoxic cytokines prevents this process in a manner similar to the 
skin inflammatory disease psoriasis (48). Eventual re-epithelialization, proliferation of 
fibroblasts, and activation of keratinocytes in the wound area promote the remodeling 
stage of wound healing, contributing to the structural rebuilding by upregulated 
production of extracellular matrix components like fibronectin and collagen (42). The 








1.4 Macrophage Roles in Immunity 
Whether in the liver (Kuppfer cells), central nervous system (microglia), bone 
(osteoclasts), lung (alveolar) or other tissues, macrophages play an important role in 
homeostatic maintenance and immune responses. They contribute extensively to innate 
immunity, and serve as a key connection between innate and adaptive immunity. In 
addition to these roles, macrophages can promote cell growth and tissue repair, regulate 
metabolic responses, and scavenge for cellular debris. Macrophages reside in many 
tissues throughout the body and each tissue-specific classification has phenotypic and 
functional properties that differentiate them from those in other tissues. In addition, the 
type and strength of response to stimuli depends strongly on local microenvironmental 
signals, resulting in myriad activation states. Despite these differences, there are various 
general functions that macrophages employ in all tissues.  
1.4.1 Macrophages in Innate Immunity 
The role of macrophages in innate immunity is of particular importance to this 
research, specifically the phagocytosis and killing of pathogens. Initiation of 
phagocytosis occurs via receptors designed to help cells recognize foreign materials. 
Macrophages express a wide variety of receptors for this purpose including Fc receptors, 
complement receptors (CR), mannose receptors (MR), and scavenger receptors. Ligation 
of these receptors leads to the polymerization of actin and subsequent ingestion of the 
pathogen into phagosomes (49). Coordination between this actin-mediated event and 
microtubule trafficking within the cell is important for the subsequent processing of the 







The phagosome can mature into the phagolysosome, designed for intracellular 
pathogen killing, through a series of fusion and fission events. Lysosomes use proton 
pumps to decrease internal pH and after fusion with phagosomes, the acidic environment 
initiates enzyme degradation of phagocytized material. Promotion of this process occurs 
via signaling events like interferon-γ signaling through STAT1 and interferon regulatory 
factor 1 (IRF-1) and TLR ligation and subsequent myeloid differentiation primary 
response 88 (MyD88) and MAPK pathways. This leads to translocation of transcription 
factors like NFκB and AP-1 to the nucleus. The increased presence of these transcription 
factors in the nucleus induces pro-inflammatory pathways that kill intracellular pathogens 
(50), a specialized ability that highlights the integral role of macrophages in innate 
immunity.  
Macrophages employ multiple strategies for killing pathogens alongside 
enzymatic degradation of pathogenic material in the phagolysosome. Macrophage 
stimulation with inflammatory cytokines (IFNγ, TNF) or TLR ligation can lead to 
production of reactive nitrogen and oxygen intermediates (51). The protein NOS2 
generates NO that diffuses into the phagolysosome due to its production location in the 
cytosol. Stimulation with IFN-γ also recruits the protein NOX2 to the phagolysosome 
where it produces reactive oxygen intermediates such as superoxide anions, hydrogen 
peroxide, and hydroxyl radicals (52). In the phagosome, the reactive nitrogen and oxygen 
intermediates can spontaneously react to form molecules that efficiently kill pathogens: 
nitrogen dioxide, peroxynitrite, dinitrogen trioxide, and more (42, 53). These can cause 
the destruction of membrane lipids, DNA, and thiol and tyrosine residues (51). 







indoleamine 2,3-dioxygenase 1 (IDO1) catabolize the essential amino acids arginine and 
tryptophan, respectively. Using a combination of these pathways enables macrophages to 
successfully kill intracellular pathogens. 
1.4.2 Macrophages in Adaptive Immunity 
While macrophages contribute significantly to innate immune responses, they also 
act as a key connection between innate and adaptive immunity via antigen presentation. 
After phagolysosomal killing, macrophages degrade foreign proteins and present the 
degraded short peptides in MHC to T cells (discussed earlier). Activation of macrophages 
via PRRs upregulates MHC, costimulatory molecule, and cytokine production, all 
necessary for T cell activation. MHC processing and presentation is extremely important 
for initiation of adaptive immune responses, as individuals with mutations in MHC 
processing proteins are susceptible to various infections (54). Macrophage antigen 
presentation, cytokine production, and costimulation emphasize the vital contributions 
macrophages make to adaptive immunity. 
1.4.3 Macrophage Regulation of Inflammation 
Despite the benefits of inflammatory responses to host immunity, they must be 
regulated to avoid immunopathologies such as those associated with autoimmune 
diseases. Macrophages support homeostasis through metabolic influences, scavenging for 
cell debris, promotion of angiogenesis, and induction of immune tolerance, helping to 
downregulate and prevent excess inflammation. However, the resolution of inflammatory 
responses by macrophages is not simply dependent on turning off inflammatory signal 
production but also by increasing the production of anti-inflammatory mediators. The 







These immunoregulatory cytokines exist to keep innate immune responses in check and, 
during later stages, to limit adaptive immunity.  
IL-10 is a potent anti-inflammatory cytokine that signals through the IL-10 
receptor on macrophages, inhibiting inflammatory cytokine production, antigen 
presentation, and frequently decreasing the killing of intracellular pathogens (55). Many 
cells produce IL-10, and genetic alterations that result in a failure to produce this 
cytokine are invariably associated with inflammatory immunopathology (56). However, 
the potent immunoregulatory activity of IL-10 has generally not led to the utilization of 
recombinant IL-10 to treat autoimmunity. Unfortunately, the administration of 
recombinant IL-10 has been largely unsuccessful at achieving a sustained reversal of 
inflammatory pathology in patients suffering with autoimmunity, including psoriasis and 
Crohn's disease (57). One reason may be that IL-10 is frequently diverted to the many 
different cells that have receptors for IL-10, preventing its delivery to inflamed areas. 
Localized induction of IL-10 may be more effective in regulating inflammation.  
Whether produced by macrophages or other cell types, IL-10 release depends on 
the strength of stimulation (57). In macrophages, increased signaling through a 
combination of stimuli results in high levels of IL-10 production. For example, the 
addition of LPS in combination with the ligation of macrophage Fc-γ receptors by high-
density immune complexes can not only induce high levels of IL-10 production but also 
potently downregulate IL-12 production (58). This reciprocal alteration in these two key 
cytokines results in a macrophage population that can mitigate inflammation and provide 
protection against acute endotoxicity (59). These macrophages also exhibit increased 







phenotypic alteration was demonstrated in an infectious disease model in which the 
intracellular parasite Leishmania uses this pathway to induce macrophage IL-10 to 
promote its survival within macrophages (60). 
Although TGF-β exhibits a wider range of roles in cellular processes when 
compared to IL-10, its ability to modulate inflammation and influence disease 
progression renders it an extremely important immune modulator. The abundance and 
activity of TGF-β ligands, the presence of SMAD cofactors, and epigenetic modifications 
all contribute to the intensity and type of signal created from TGF-β signaling (61). 
SMAD proteins, activated via the TGF-β receptor, form complexes with each other and 
with other cofactors to activate or inhibit gene transcription. The addition of exogenous 
TGF-β to LPS-stimulated macrophages decreased the release of proinflammatory 
cytokines, suggesting paracrine functions of the signaling (62). In mouse models, TGF-β 
treatment prevented disease in collagen-induced arthritis and prevented relapse in 
rheumatoid arthritis, consistent with its anti-inflammatory activity (63). Use of TGF-β as 
a therapeutic in mouse models for multiple sclerosis showed improved clinical status and 
decreased nervous system damage, indicating its promise (64). However, the multifaceted 
effect of TGF-β production is illustrated by its contribution to fibrotic diseases, showing 
the need to continue studying this complex pathway (65). 
The previous paragraphs detailing IL-10 and TGF-β were adapted from the previously 
published work: Hamidzadeh K, Christensen SM, Dalby E, Chandrasekaran P, Mosser 
DM (2017) Macrophages and the Recovery from Acute and Chronic Inflammation. Annu 
Rev Physiol 79:567–592. 







 Classification of macrophage activation states has evolved over the years as we 
continue to uncover the complexities of macrophage plasticity. Originally, macrophages 
were categorized as either classically activated (M1) or alternatively activated (M2) (66). 
The classical activation (M1) characterization is widely accepted, utilizes IFNγ/LPS 
stimulation, and translates well to human models. “Classically activated” macrophages 
secrete inflammatory cytokines and recruiting chemokines and produce high levels of 
superoxides designed to kill engulfed pathogens in the phagolysosome (13). However, 
growing knowledge indicates that the spectrum of macrophage activation is much more 
complex, involving more than 2 activation states, and this oversimplification can lead to 
confusion. Activation via IL-4 or IL-13 (M2a), known to promote Th2 responses and 
contribute to wound healing through angiogenic and fibrotic factors, is well classified in 
the murine system (13, 67–70). However, markers of M2 murine macrophages do not 
translate well into human systems, and research has struggled to identify markers of 
human M2a macrophages (70, 71). The so-called regulatory macrophages, also called 
M2b (69), have been generated via stimulation with TLR ligands in conjunction with 
immune complexes, prostaglandin, adenosine, or apoptotic bodies. These macrophages 
potently downregulate IL-12, upregulate IL-10, and secrete growth and angiogenic 
factors. Our lab has begun to identify markers of human regulatory macrophages and 
apply them to the disease model leishmaniasis in this work.  
1.5 Leishmaniasis 
 Infections from Leishmania species present in a wide range of clinical 
characterizations and we still lack a full understanding of the host-pathogen interactions 







manifests as either cutaneous infections in the skin or visceral infections that are systemic 
and potentially fatal (72). This work pertains to cutaneous leishmaniasis, an infection 
that, while rarely fatal, can cause disfiguration and a significant reduction in quality of 
life. Following the bite of an infected female phlebotomine sandfly, disease manifestation 
relies strongly on the species of parasite present, a panel of over 20 known species 
throughout the globe. More than 90% of cutaneous leishmaniasis cases occur in only 
twelve countries: Afghanistan, Algeria, Brazil, Colombia, Iran, Iraq, Morocco, Peru, 
Saudi Arabia, Sudan, Syrian Arab Republic, and Tunisia (73). Patients of Old World 
cutaneous disease (mainly eastern hemisphere) do not usually require treatment due to the 
spontaneous, self-healing nature of the lesions. However, treatment of New World 
cutaneous leishmaniasis is recommended and usually involves administration of 
antimonials, despite the many adverse side-effects of these toxic drugs. Leishmaniasis is 
classified as a “neglected tropical disease” (NTD) by the WHO due to struggles in 
vaccine and therapeutic advancements to effective clinical stages, stressing the need for 
further research. 
Cutaneous lesions can be split into four types of disease: localized cutaneous 
(LCL), diffuse cutaneous (DCL), disseminated (DL), and mucocutaneous (MCL). The 
four main cutaneous clinical classifications reside on a spectrum of pathology, ranging 
from hyposensitive to hypersensitive (Figure 1) (74). At the hyposensitive end, DCL 
patients show no delayed-type hypersensitivity (DTH) response, exhibit large numbers of 










Figure 1. Spectral nature of leishmaniasis Representation of the spectral nature of leishmaniasis 
infections. Severe disease resides at each end of the spectrum in diffuse cutaneous lesions (DCL) or 
mucocutaneous lesions (MCL). Hyposensitive DCL patients are typically DTH negative, indicative of 
failure to produce cell-mediated immunity and Th1 cells. DCL contains high numbers of parasite in lesions, 
high IL-10 in lesions, and increased serum antibody. Hypersensitive mucocutaneous lesions are 
characterized by increased IFNγ, low parasite numbers, and immense tissue damage. Localized and 
disseminated leishmaniasis spontaneously self-heal and are considered moderate disease. Localized disease 
manifests as a single nodule that can progress to an ulcerated lesion, while disseminated disease manifests 
as multiple acneiform and papular lesions. LCL and DL patients do have a DTH positive response. 
Localized disease is the most common manifestation; DCL, DL, and MCL are considered rare. Figure 





















At the other end of the spectrum, MCL pathology is mainly immune-mediated with an 
intense DTH response, high levels of IFNγ, low parasite numbers, and tissue damage that 
can lead to disfiguring disease. Less hypersensitive than MCL, lesions in DL and LCL 
patients are still on the hypersensitive end of the spectrum, with uncontrolled Th1 
responses sometimes associated with ulcerated lesions.  
The Leishmania life cycle consists of mammalian hosts and the sandfly vector. 
Parasites become metacyclic and highly infective in the gut of the sandfly, allowing for 
rapid infection of host macrophages and dendritic cells after the blood meal is taken. 
Once in macrophages, the parasites survive and replicate as amastigotes in the 
phagolysosome, inhibiting macrophage killing. The phagolysosome eventually bursts and 
the Leishmania are taken up by neighboring phagocytes, perpetuating the cycle and 
spreading the parasite through the tissue. Parasites return to the sandfly vector when it 
takes a blood meal from an infected individual.  
1.5.1 Immune responses in leishmaniasis 
Dating back 30 years, murine models have helped to characterize resistant and 
susceptible species of mice based on the prevalence of a Th1 or Th2 immune response, 
respectively (75, 76). Activated professional phagocytes will migrate to lymph nodes 
where they present antigen to T cells. The activation state of CD4+ helper T cells in 
murine models relies heavily on the cytokines IL-12 (Th1) or IL-4 (Th2). Th1 cells 
produce IFNγ and TNF, molecules that classically activate macrophages to kill the 
intracellular parasite (77–79). “Improper” Th2 responses, generated via the production of 
IL-4 and IL-13 signaling through IL-4 receptor-alpha result in alternative macrophage 







susceptible mice (80). Additionally, susceptibility has not surprisingly been tied to anti-
inflammatory IL-10 production as well. Mice deficient in IL-10 are highly resistant to 
infection from multiple species (81–83).  
Despite this seemingly simple dichotomy, timing and strength of signal can also 
play an important role in determining protection and susceptibility. Resistant mice 
actually produce small amounts of IL-4 during the early response to infection but it does 
not appear to be sufficient to affect the Th1 outcome (84). Treatment of susceptible mice 
with IL-12 plus anti-IL-4 antibody at one month after infection shifted responses toward 
Th1 and decreased parasite burden and lesion size (85). Conversely, treatment of 
susceptible mice with IL-4 within hours of infection can lead to protective and Th1 
responses in dendritic cells (DCs) (86). These complexities that are observed in inbred 
strains of mice emphasize the need for further study, especially in human models.  
In human Leishmania infection, aspects of Th1 resistance and Th2 susceptibility 
have been uncovered but controversy remains. Both Th1 and Th2 cytokines have 
previously been observed in LCL, MCL, and DCL (87, 88). Santos et al. have highlighted 
the role of IFNγ production by Th1 cells in parasite clearance (89). Although high levels 
of IFNγ and TNF correlate well to decreased parasite burden, uncontrolled Th1 cytokine 
production drives immunopathology in localized and mucocutaneous infections from L. 
braziliensis (90, 91). Inferences of IL-4 contributions to susceptibility or parasite 
persistence via peripheral blood, lesions, and cultured cells has been observed in some 
cases (92–96), but not others (91, 97, 98). Research has shown the presence of IL-13, but 
not IL-4, in response to Leishmania antigen after healing (99). In ex vivo studies, 







peripheral blood mononuclear cells (PBMCs) but IL-10 antibody or IL-12 protein did 
(100). Indeed, human cutaneous leishmaniasis lesions contain high levels of IL-10 and 
TGFβ (87, 94, 101, 102). These combined findings suggest that perhaps IL-4 is not as 
large a contributor as originally believed and human susceptibility relies more on the 
balance between IL-12/IFNγ and IL-10/TGFβ. 
In addition to studies on T helper cell contributions to human cutaneous lesions, 
other studies have shown contributions of CD8 T cells in the healing process and 
resistance to Leishmania infection (103, 104). Conversely, cytotoxic T cell production of 
granzymes can lead to extensive tissue damage (89). The exact role of these cells in 
resolution or pathology seems to depend on production of either IFNγ or cytolytic 
molecules, but further analyses are required (72). 
The majority of leishmaniasis research has focused on phagocytic cell killing of 
parasites as well as T cell influences on infection. The focus on these cells is warranted, 
yet research has increasingly shown the importance of other cells in the control or 
persistence of disease. Infiltration of T cells, macrophages, B cells, NK cells, and 
granulocytes into lesions has previously been shown but until recently some of these cell 
types were not extensively studied (105). Contemporary research shows early neutrophil 
responses acting as a Trojan horse to protect parasites during initial infection (106). An 
increasingly wide range of T cell populations have been implicated in infection resolution 
and pathology and T cell anergy has been shown to promote parasite survival (103, 107–
110). Vaccine research has focused on the stimulation of NK cell cytotoxicity in 
preventing infection (111). Even still, the contributions of keratinocytes to immune 







known (60, 113, 114), but studies on B cell subsets and their contribution to parasite 
persistence or killing are still in early stages. 
The role of B cells and immunoglobulin production is especially pertinent to this 
work and previous works have pointed to complex and varied roles for immunoglobulin 
contributions to Leishmania infection. Uptake of Leishmania by phagocytes can occur 
through FcR-mediated phagocytosis (115), a process known to induce IL-10 production 
in macrophages (58, 116). In fact, Fc receptors and IgG exacerbated disease and are 
needed to establish infection in mice (60, 113, 117–120). In humans, levels of serum IgG 
vary depending on parasite species and clinical manifestation. High levels of IgG are tied 
to L. amazonensis in DCL patients and also in visceral leishmaniasis (60, 121–123). 
Although IgG has been shown to be protective against intracellular pathogens (124), this 
does not seem to be the case for Leishmania. However, it has been suggested that IgG2a 
in mice may contribute to lesion resolution (117) and vaccine development has focused 
on inducing IgG2a in mice and dogs to curate a Th1 bias that promotes healing (125–
128).  
1.5.2 Immune Evasion by Leishmania 
Leishmania sp. have developed numerous methods to avoid killing and promote 
survival within host macrophages and dendritic cells. During initial infection after the 
sandfly bite, parasites are able to avoid complement activation using the glycoprotein 
GP63, which cleaves the complement protein C3 into its inactive C3bi form. This not 
only prevents the formation of the membrane attack complex (129), but also serves as an 
opsonin that directs phagocytes to engulf the pathogen (130, 131). Once inside the cell, 







arginase, and inhibit inflammatory signals such as phagolysosome maturation and 
costimulatory molecule production (132–134). At the same time, induction of IL-10, IL-
4, IL-5, PGE2, and TGF-β also have been shown during infection (135). While the 
specifics are known for some manipulations, a complete framework of the host-pathogen 
interaction is lacking. 
Research has identified some of the various proteins and pathways that 
Leishmania use to evade and even harness the immune response for their advantage. One 
of the most commonly known virulence factors is glycoprotein 63 (GP63). This protein 
has been shown to be multifunctional in parasite virulence, not just in cleaving C3 as 
described earlier. GP63 can cleave PKC substrates necessary for oxidative bursts (136). 
Cleavage of RelA subunits by GP63 and other cysteine peptidases induces chemokines 
that aid parasite survival (137, 138). GP63 can also cleave c-Jun and c-Fos to prevent the 
transcription factor AP-1 from inducing intracellular killing (139) and cleave mTOR to 
promote parasite survival (140). The surface protein lipophosphoglycan (LPG) is another 
virulence factor that has been shown to facilitate binding to multiple proteins on 
macrophage membranes (135) to encourage phagocytosis of the parasite. Once inside the 
cell, Leishmania LPG can inhibit endosome maturation (141) and phagosome 
acidification (142) and “quench” superoxide radials (143). LPG can also inhibit the 
induction of the monocyte chemoattractant CCL2 (144). Leishmania require iron for 
growth and counteract host iron efflux from the phagosome through the parasite iron 
transporter protein LIT1 (145). While these virulence factors are known, full annotation 
of parasite genomes is still lacking. Our investigation of the parasite transcriptome in 








 The complexities of the immune system allow organisms, from flies to humans, to 
defend against pathogens, recover from injury, maintain homeostasis, and much more. 
Divided into two branches, the immune system is poised to react to acute injury or 
infection (innate immunity) while also providing immune memory (adaptive immunity). 
Myriad cell types, signaling cascades, and checks and balances contribute to the efficacy 
of innate and adaptive immune responses. While the complexities of the immune system 
demonstrate its ability to defend against a plethora of pathogens, it also provides 
numerous ways for pathogens to evade and even control responses for their benefit. One 
of these, the tropical parasite Leishmania, infects millions of people each year who suffer 
from a spectrum of disfiguring and fatal disease. Effective vaccines are not available and 
safe therapeutics remain in developmental stages of production. In order to further 
understand leishmaniasis microenvironments and host-pathogen interactions, I describe 
the host and parasite transcriptomes in two forms of the disease: localized cutaneous 
leishmaniasis in L. braziliensis-infected patients and diffuse cutaneous leishmaniasis in L. 
amazonensis-infected patients. In-depth characterization of host and parasite gene 
expression could elucidate biomarkers or targets for effective vaccines and therapeutics, 







Chapter 2: Materials and Methods 
2.1 RNA Sequencing and Transcriptomics 
2.1.1 Background Methods to examine the transcriptome have advanced in recent years, 
from hybridization to sequence-based techniques. Custom-made microarrays are high-
throughput and less expensive, relying on hybridization of fluorescently-labeled cDNA to 
gene-specific constructs that allows for relative gene expression comparisons. However, 
this technology is deficient in numerous ways: being restricted to a subset of gene probes, 
limited on distinguishing low or high expression levels, and difficult to compare across 
experiments. Rapidly improving sequence-based technologies like RNA-seq remedy 
these limitations and provide a deeper understanding of the transcriptome. RNA-seq 
methods can map reads to an entire genome, not just a subset, and can even be used for 
de novo assembly of previously unsequenced genomes. This technology is not limited to 
probes and allows for single base pair resolution that illuminates exactly where 
transcription starts, ends, skips (introns and exons) (146), and even varies (SNPs) (147). 
On one end, there is little to no background noise in RNA-seq output that permits 
inclusion of lowly expressed genes, while on the other end, there is no upper limit to the 
quantity of reads mapping to any single region. Additionally, comparisons across 
experiments requires less strenuous normalization methods. The most important aspect of 
RNA-seq applicable to this work is the ability to simultaneously analyze the 
transcriptomes of multiple species. Using RNA isolated from infected human tissue, we 
can simultaneously map reads to human and pathogen genomes. 
2.1.2 Experimental Application The goal of this research was to better understand the 







both species during infection. Previous work by our collaborators used microarray 
technology to examine LCL lesions in L. braziliensis-infected patients, characterizing a 
general signature of immunopathology and identifying enriched pathways, citing 
commonalities between LCL and psoriasis lesions (48). To expand upon these results and 
develop a better understanding of the host and parasite transcriptome, we performed 
RNA-seq on the LCL biopsies and mapped reads to the human and parasite genomes. We 
further acquired biopsies from DCL patients and performed RNA-seq on these samples as 
well, enabling us to compare and contrast two different manifestations of cutaneous 
disease from the human and parasite perspectives. The results are detailed in the 
subsequent chapters of this dissertation. 
2.1.3 RNA isolation and cDNA library preparation. Samples were placed in RNAlater 
and homogenized using a rotor-stator. Total RNA was isolated using the RNeasy Plus Kit 
from Qiagen (Hilden, Germany). RNA integrity was assessed using an Agilent 2100 
bioanalyzer. Poly(A)+-enriched cDNA libraries were generated using the Illumina TruSeq 
Sample Preparation kit (San Diego, CA) and checked for quality and quantity using the 
bioanalyzer and quantitative polymerase chain reaction (qPCR) (KAPA Biosystems). 
2.1.4 RNA-seq data generation, pre-processing, and quality trimming. Paired end 
reads (~100 bp) were obtained using the Illumina HiSeq 1500 platform. Trimmomatic 
(148) was used to remove any remaining Illumina adapter sequences from reads and to 
trim bases off the start or the end of a read when the quality score fell below a threshold 








2.1.5 Mapping cDNA fragments to the reference genome, abundance estimation, and 
data normalization. TopHat (v 2.0.13) (149) was used to align reads to the applicable 
genome(s) with each genome alignment performed independently. Reads from healthy, 
LCL, and DCL skin samples were aligned to the human genome (v. hg19/GRCh37) 
obtained from the UCSC genome browser (http://genome.ucsc.edu). Reads from LCL 
and DCL infection samples were additionally aligned to the L. braziliensis (v. 
MHOM/BR/75M2904, Sanger Institute) or L. mexicana (v. MHOM/GT/2001/U1103) 
genomes respectively, obtained from the TriTrypDB database (www.tritrypdb.org). Two 
mismatches per read were permitted (default TopHat parameter) and reads were allowed 
to map only to a single locus (TopHat option –g 1). Additionally, gene model annotations 
were provided for the mapping (TopHat option –G) with limitations on the identification 
of novel splice junctions (TopHat option –no-novel-juncs). The abundance of reads 
mapping to each gene feature in the aligned genome was determined using HTSeq (150). 
Each resulting count table was restricted to protein-coding genes: 20,956 genes for 
human, 8,556 genes for L. braziliensis, 8,336 for L. amazonensis. Non-expressed and 
weakly expressed genes, defined as having less than 1 read per million in n of the 
samples, where n is the size of the smallest group of replicates (151) (here n=8 for human 
and L. braziliensis, n=6 for L. amazonensis), were removed prior to subsequent analyses, 
resulting in count tables of 15,256 (human), 8,556 (L. braziliensis), and 8,336 genes (L. 
amazonensis). 
2.1.6 Global data assessment, visualization and differential expression analysis. 
Quantile normalization was applied to all samples (152) and data were log2-transformed. 







between samples, including Pearson correlation and Principal Component Analysis 
(PCA). Limma (a Bioconductor package) was used to conduct differential expression 
analyses (153). The voom module was used to transform the data based on observational 
level weights derived from the mean-variance relationship prior to statistical modeling 
(154). Pairwise contrasts were done within limma to identify differentially expressed 
(DE) genes between conditions. Genes with a Benjamini-Hochberg (BH) multiple-testing 
adjusted P value of < 0.05 were defined as differentially expressed. Components of our 
statistical pipeline, named cbcbSEQ, can be accessed on GitHub 
(https://github.com/kokrah/cbcbSEQ/).  
2.1.7 Immunoglobulin sequencing analysis Using filtered and trimmed sequences from 
the aforementioned pre-processing, reads were aligned and filtered using miXCR and 
pRESTO (155, 156). After preparation, sequences were collapsed and submitted to the 
ImMunoGeneTics database (IMGT) HighV-QUEST web server for gene annotation and 
analysis (157, 158). IMGT output was analyzed using in house scripts and bcREP (159).  
2.2 Ethics Statement 
These studies were conducted according to the principles specified in the 
Declaration of Helsinki and under local ethical guidelines and this study was approved by 
the Ethics Committees of the Federal University of Bahia (Salvador,Bahia, 
Brazil)(010/10), University of Maryland (College Park)(925281-2) and the University of 
Pennsylvania IRB (Philadelphia, Pa)(813390). All patients provided written informed 









2.3 Patients and Procedures 
All localized cutaneous leishmaniasis (LCL) patients were seen at the health post in Corte 
de Pedra, Bahia, Brazil, an area endemic to L. braziliensis. Diagnosis consisted of visual 
confirmation of a lesion characteristic of LCL and parasite DNA detection and/or a 
positive delayed-type hypersensitivity response to Leishmania antigen. Biopsies were 
collected at the border of the lesions using a 4 mm punch before therapy. Patients 
consisted of 15 males and 10 females with illness duration ranging from 15 to 90 days 
and lesion sizes ranging from 4-960 mm2 (Table 1). Healthy (uninfected) skin samples 
were taken from volunteers living in a non-endemic area without a history of 
leishmaniasis, as described (48). All diffuse cutaneous leishmaniasis (DCL) patients were 
seen at Institute Evandro Chagas, Professor Ralph Lainson Laboratory of Leishmaniasis, 
Ananindeua, Para Brazil. Biopsies were collected at the border of the lesions using a 4 
mm punch. Patients consisted of 5 males and 1 female with illness duration ranging from 















N1	 Uninfected	 NA	 NA	 NA	 NA	
N2	 Uninfected	 NA	 NA	 NA	 NA	
N3	 Uninfected	 NA	 NA	 NA	 NA	
N4	 Uninfected	 NA	 NA	 NA	 NA	
N5	 Uninfected	 NA	 NA	 NA	 NA	
N6	 Uninfected	 NA	 NA	 NA	 NA	
N7	 Uninfected	 NA	 NA	 NA	 NA	
N8	 Uninfected	 NA	 NA	 NA	 NA	
N9	 Uninfected	 NA	 NA	 NA	 NA	
N10	 Uninfected	 NA	 NA	 NA	 NA	
E1	 Early	infection	 36	 21	 44	 F	
E2	 Early	infection	 40	 21	 24	 M	
E3	 Early	infection	 56	 15	 31	 F	
E4	 Early	infection	 12	 20	 25	 F	
E5	 Early	infection	 80	 20	 33	 M	
E6	 Early	infection	 120	 15	 25	 F	
E7	 Early	infection	 25	 30	 30	 F	
E8	 Early	infection	 4	 15	 40	 M	
L1	 Late	infection	 100	 30	 25	 M	
L2	 Late	infection	 440	 37	 28	 M	
L3	 Late	infection	 100	 90	 19	 M	
L4	 Late	infection	 560	 90	 33	 F	
L5	 Late	infection	 180	 60	 18	 M	
L6	 Late	infection	 252	 30	 27	 M	
L7	 Late	infection	 100	 30	 45	 F	
L8	 Late	infection	 48	 30	 21	 M	
L9	 Late	infection	 550	 30	 37	 M	
L10	 Late	infection	 380	 60	 25	 M	
L11	 Late	infection	 250	 30	 30	 M	
L12	 Late	infection	 100	 35	 33	 F	
L13	 Late	infection	 440	 40	 25	 M	
L14	 Late	infection	 192	 25	 19	 F	
L15	 Late	infection	 400	 30	 40	 M	
L16	 Late	infection	 48	 45	 26	 F	









Table 2. Patient metadata for DCL biopsies 
Patient Patient age 
(years) 
Gender Illness duration at time of 
biopsy (years) 
DCL.1 50 F 22 
DCL.2 42 M 35 
DCL.3 43 M 20 
DCL.4 37 M 34 
DCL.5 30 M 27 








Chapter 3: Meta-transcriptome profiling of the human-Leishmania 
braziliensis localized cutaneous lesion 
Adapted from previous publication: Christensen SM, Dillon LAL, Carvalho LP, Passos S, 
Novais FO, Hughitt VK, Beiting DP, Carvalho EM, Scott P, El-Sayed NM, Mosser, DM. 
Meta-transcriptome Profiling of the Human-Leishmania braziliensis Cutaneous Lesion. 
PLoS Negl Trop Dis. 2016. 
ABSTRACT 
Host and parasite gene expression in skin biopsies from Leishmania braziliensis-infected 
patients were simultaneously analyzed using high throughput RNA-sequencing. Biopsies 
were taken from 8 patients with early cutaneous leishmaniasis, 17 patients with late 
cutaneous leishmaniasis, and 10 healthy volunteers. Although parasite DNA was found in 
all patient lesions at the time of biopsy, the patients could be stratified into a group that 
lacked detectable parasite transcripts (PTNeg) in lesions and another group in which 
parasite transcripts were readily detected (PTPos). These groups exhibited substantial 
differences in host responses to infection. PTPos biopsies contained an unexpected 
increase in B lymphocyte-specific and immunoglobulin transcripts in the lesions, and an 
upregulation of inflammatory and immune inhibitory molecules. Biopsies without 
detectable parasite transcripts showed decreased evidence for B cell activation, but 
increased expression of antimicrobial genes and genes encoding skin barrier functions. 
The composition and abundance of L. braziliensis transcripts in PTPos lesions were 
surprisingly conserved among all six patients, with no differences between lesions from 
patients with early and late cutaneous leishmaniasis. Some of the most highly expressed 







virulence factors, as well as histones and tubulin. We compared parasite gene expression 
to previously sequenced data of in vitro macrophage infections. Despite some 
similarities, overall parasite expression differed between the lesion and laboratory 
environments, suggesting a varied parasite response due to immune stress. In summary, 
RNA-seq allowed us to simultaneously analyze human and L. braziliensis transcriptomes 
in lesions of infected patients, and identify unexpected differences in host immune 
responses correlated with active transcription of parasite genes. 
INTRODUCTION 
Leishmaniasis is characterized as a spectral disease, with clinical presentations 
ranging from a self-healing cutaneous form of the disease to a visceral form associated 
with high morbidity and mortality. The immune response to the various species is also 
spectral in nature, with L. donovani inducing minimal immune responses or actually 
inhibiting inflammation and immunity (160), and L. braziliensis inducing immune 
activation and immune-mediated pathology (103). L. braziliensis is the causative agent of 
tegumentary leishmaniasis in South America. Approximately 3-5% of patients infected 
with L. braziliensis will eventually develop mucocutaneous disease, a disfiguring 
manifestation involving the nasal and oropharyngeal mucosa (161). L. braziliensis 
infections are typically associated with a strong Th1 response and a positive skin test 
response to soluble leishmanial antigens characterized by high levels of TNF and IFN-γ 
(90).  
 ‘Early’ L. braziliensis lesions frequently present as a small papule that can 
eventually progress to larger ‘late’ ulcerative lesions, typically containing small numbers 







increased cytokine responses and increased T cell proliferation responses to parasite 
antigens (90). The robust immune response to this organism despite low or undetectable 
numbers of parasites in lesions, and the increased immune responses in mucocutaneous 
forms of the disease have led to the suggestion that exaggerated Th1 host immune 
responses contribute to the pathological tissue damage associated with L. braziliensis 
infections (162). Recent studies suggest that a major factor in the development of disease 
caused by L. braziliensis is the recruitment of cytolytic CD8+ T cells that promote 
increased inflammation (89, 107). 
Immune responses in the skin of infected patients may not be accurately reflected 
by the type and magnitude of host responses in peripheral blood. Previous studies using 
immunohistochemistry have described the infiltration of T cells, macrophages, B cells, 
NK cells, and granulocytes into lesions (105, 163, 164). Some research has implicated 
CCR2-positive monocytes in parasite killing (165, 166), while other studies have 
described the contribution of the skin micro-environment to the local immune response 
(167–170). For these reasons, a meta-transcriptomic profiling of lesions may provide a 
more complete picture of host and parasite responses during infection.  
A microarray-based transcriptomic profiling of skin lesions from patients infected 
with L. braziliensis was recently reported (48). This work showed an association between 
chemokines and cytotoxic T cell responses and disease-associated pathology. We 
extended this work using RNA-seq to simultaneously analyze host and parasite 
transcripts in these lesions. This approach allowed the detection of parasite transcripts 
expressed in the skin of infected patients, and revealed unexpected differences in the host 







revealed L. braziliensis transcripts most abundantly produced in human lesions of 
localized cutaneous leishmaniasis. 
RESULTS 
Global data assessment, visualization and differential expression analysis. Samples were 
classified as PTPos and PTNeg based on the percentage of reads mapping to the L. braziliensis 
genome. Parasite detectable-positive samples were defined as those with more than 0.5% of 
reads mapping to the parasite genome. In the six PTpos samples, the average proportion of reads 
that mapped to the parasite genome was 0.98%, for an average of 867,489 parasite reads per 
tissue sample sequenced to an average depth of 88 million reads. The 10 PTNeg samples were 
defined as those with fewer than 0.01% reads mapping to the parasite; the proportion of reads 
in the PTNeg samples that mapped to the parasite genome was not different than the 10 healthy 
controls. We designated nine additional samples as PTInt because they expressed low levels of 
transcripts (between 0.01-0.2% of total reads) that could only tentatively be assigned to the 
parasite. The number of parasite reads in this group was too low to provide a meaningful 
analysis of parasite gene expression and therefore they were excluded from the PTPos group. 
The human host transcriptome in lesions of L. braziliensis infected patients. RNA-
seq analysis was performed on biopsies from 10 healthy and 25 L. braziliensis infected 
patients. Principal Component Analysis (PCA) (Figure 2A) and hierarchical clustering 
(Figure 3A) of the human transcriptome data revealed distinct differences between 
healthy skin and lesions from infected patients, as expected. Lesions are clinically 
defined as either ‘early’ (small papule, no ulceration, ≤ 30 days illness duration) or ‘late’ 








Figure 2. Human and parasite transcriptomes in lesions of L. braziliensis infected patients. (A) 
Principal component analysis (PCA) of human transcriptomes from 10 healthy volunteers (light gray) and 
25 L. braziliensis-infected patients (dark gray) is shown. The first two principal components (PC) are 
displayed on each axis along with the variance (56.79% and 7.61%). (B) Principal component analysis 
(PCA) plot of human transcriptomes from 8 early-stage (pink), and 17 late-stage (maroon) leishmaniasis 
patients. The first two principal components (PC) are displayed on each axis along with the variance 
(24.91% and 12.64%). (C) The percentage of total reads that mapped to the Leishmania braziliensis 
genome from each of the 25 infected patient samples are plotted as bars. The samples containing > 0.5% 
reads are labeled as parasite transcript positive (PTPos, orange), 0.01-0.5% reads as parasite transcript 
intermediate (PTInt, yellow), and the rest < 0.01% reads as parasite transcript negative (PTNeg, blue). (D) 
PCA plot of patient samples grouped according to parasite transcript levels: PTNeg (blue), PTInt (yellow), 
and PTPos (orange). The first two principal components (PC) are displayed on each axis along with the 
variance (24.91% and 12.64%).  








































































































































































































































Figure 3. Comparisons of L. braziliensis lesions (3A) Panel A shows a heatmap enriched pathways (using 
GSEA) comparing healthy controls (gray line, top) and leishmaniasis patients (orange line). 680 pathways 
showed ≥2 fold differences that were clustered hierarchically. (3B) Principal component analysis (PCA) 
plot of human transcriptomes from 15 female (light gray), and 10 male (dark gray) leishmaniasis patients. 
The first two principal components (PC) are displayed on each axis along with the variance (24.91% and 
12.64%). (3C) Principal component analysis (PCA) plot of human transcriptomes from 25 leishmaniasis 
patients, colored by lesion size. The first two principal components (PC) are displayed on each axis along 
with the variance (24.91% and 12.64%). (3D) Principal component analysis (PCA) plot of human 
transcriptomes from 25 leishmaniasis patients, colored by illness duration. The first two principal 
components (PC) are displayed on each axis along with the variance (24.91% and 12.64%). (3E) Principal 
component analysis (PCA) plot of human transcriptomes from 25 leishmaniasis patients, colored by patient 
age. The first two principal components (PC) are displayed on each axis along with the variance (24.91% 
and 12.64%). (3F) 3-D Principal component analysis (PCA) plot of human transcriptomes from 25 
leishmaniasis patients, colored by parasite transcript displayed on each axis (PC1: 24.91%, PC2: 12.64%, 
PC3: 11.89%). 
  
























































































Within the group of biopsies from the 25 infected individuals, there were minimal 
appreciable differences in host responses between patients with early and late cutaneous 
leishmaniasis (Figure 2B, Table 3), as previously reported (48). There was also no 
separation in host responses as a function of sex (Figure 3B), lesion size (Figure 3C), 
illness duration (Figure 3D), or age (Figure 3E). 
RNA-seq allows the simultaneous analysis of both host and parasite 
transcriptomes, and we sought to determine whether the presence or absence of 
detectable parasite transcripts in lesions could impact host responses. Lesions from six of 
the patients were considered parasite transcript positive (PTPos) when greater than 0.5% 
of the total reads mapped to the parasite genome (Figure 2C, orange). Ten lesions were 
considered parasite transcript negative (PTNeg) because less than 0.01% of the total reads 
mapped to the parasite (Figure 2C, blue). This is the same proportion of parasite reads 
that map non-specifically to highly conserved homologous sequences in the human 
genome. Nine lesions were considered parasite transcript intermediate (PTInt) when 
percent reads ranged from 0.01-0.2 (Figure 2C, yellow). The number of parasite reads in 
this group was too low to provide a meaningful analysis of parasite gene expression, and 
therefore they were excluded from the PTPos group. By PCA, there was a clear separation 
in host responses of the PTPos (Figure 2D, orange) and PTNeg groups (Figure 2D, blue, 
note dashed line separating blue and orange), with the PTInt group (Figure 2D, yellow) 
falling in between these two. This separation between groups becomes even more 
obvious with the addition of the third principal component, accounting for 11.89% of the 








Table 3. Differential expression between early and late cutaneous L. braziliensis 
lesions 
  
ID Symbol logFC adj.P.Val 
ENSG00000137857 DUOX1 1.101722038 0.040 
ENSG00000180921 FAM83H 1.048863823 0.047 
ENSG00000119514 GALNT12 -1.313526975 0.036 
ENSG00000137869 CYP19A1 -1.402417898 0.049 
ENSG00000143867 OSR1 -1.566920662 0.046 
ENSG00000105825 TFPI2 -2.306474341 0.015 
ENSG00000124212 PTGIS -2.392557657 0.014 
ENSG00000116690 PRG4 -2.724259154 0.015 
ENSG00000188257 PLA2G2A -3.212912709 0.015 
ENSG00000004799 PDK4 -3.237094127 0.015 
ENSG00000170323 FABP4 -3.633646574 0.023 
ENSG00000000005 TNMD -3.790990591 9.53E-05 







Thus, there is a surprising separation of host responses, depending on the presence or 
absence of detectable parasite transcripts in lesions, allowing us to correlate host 
responses with parasite elimination or persistence. 
Host transcriptomic responses in PTPos and PTNeg samples. We found large 
differences in host transcripts between healthy controls and infected patients, as expected, 
with 4579 host genes being differentially expressed in lesions relative to normal skin 
using a cutoff fold change > 2 and P value < 0.05. A total of 3884 differentially 
expressed genes were common to PTNeg and PTPos, but there was a total of 477 
differentially expressed genes unique to PTPos lesions (Figure 4A, orange circle) and 241 
differentially expressed genes unique to PTNeg lesions (Figure 4A, blue circle), relative to 
healthy controls.  
The intermediate (PTInt) samples shared 3817 differentially expressed genes with 
PTNeg and PTPos, as well as an additional 987 genes with PTPos and 214 genes with PTNeg. 
A total of 238 genes showed differential expression unique to the PTInt group (Figure 4A, 
yellow circle). Tables 4 and 5 show some of the direct comparison between gene 
expression in PTPos and PTNeg lesions. Twenty-five of the top 30 upregulated genes in 
PTPos lesions relative to PTNeg lesions encoded immunoglobulin fragments, including 9 of 
the top 10 genes (Figure 4B, black bars). This group also included CXCL8 (granulocyte 
migration), IL-21 (B cell proliferation), and granulysin (cellular cytotoxicity). The genes 
most highly expressed in PTNeg lesions relative to PTPos lesions included genes involved 
in skin defenses and epidermal cell development. The top 10 genes in this category 
included loricrin, filaggrin-1, filaggrin-2, and hornerin, all involved in skin development 









Figure 4. Comparison of human host transcriptomes in lesions with parasite detectable-positive 
transcripts (PTPos) versus parasite detectable-negative (PTNeg) transcripts. (A) Venn diagram showing 
differentially expressed genes in three patient populations compared to healthy controls (HC): PTPos 
(orange circle), PTNeg (blue circle), PTInt (yellow circle). (B). The top ten significantly upregulated (black) 
and downregulated (light gray) genes when comparing PTPos to PTNeg (mean plus SEM). (C) Shown are the 
25 immunoglobulin genes exhibiting the highest differential expression between PTNeg and PTPos samples. 
Bars depict the fold change in expression in PTNeg (blue), PTInt (yellow), and PTPos (orange) samples 








Table 4. Top 50 upregulated genes in PTPos compared to PTNeg 
Symbol Description logF
C 
IGHV3-9 immunoglobulin heavy variable 3-9  4.08 
IGLV3-27 immunoglobulin lambda variable 3-27 3.88 
IRG1 immunoresponsive 1 homolog 3.77 
IGHV3-73 immunoglobulin heavy variable 3-73 3.77 
IGHV3-20 immunoglobulin heavy variable 3-20 3.68 
IGLV3-9 immunoglobulin lambda variable 3-9 3.67 
IGHV1-58 immunoglobulin heavy variable 1-58 3.57 
IGHV1-2 immunoglobulin heavy variable 1-2 3.55 
IGLC7 immunoglobulin lambda constant 7  3.47 
IGHV3-48 immunoglobulin heavy variable 3-48  3.43 
IGHV1-69 immunoglobulin heavy variable 1-69 3.42 
IGKV1-27 immunoglobulin kappa variable 1-27 3.39 
IGHV3-21 immunoglobulin heavy variable 3-21  3.38 
IGKJ5 immunoglobulin kappa joining 5  3.36 
IGHV1-8 immunoglobulin heavy variable 1-8  3.31 
IGHV3-23 immunoglobulin heavy variable 3-23  3.29 
IGHG3 immunoglobulin heavy constant gamma 3 (G3m marker)  3.28 
IGLV3-21 immunoglobulin lambda variable 3-21  3.28 
IGLV3-1 immunoglobulin lambda variable 3-1 3.26 
IGLV1-44 immunoglobulin lambda variable 1-44  3.25 
IGKV1D-8 immunoglobulin kappa variable 1D-8  3.23 
IGKV1D-33 immunoglobulin kappa variable 1D-33  3.21 
LAG3 lymphocyte-activation gene 3  3.17 
IGHV3-15 immunoglobulin heavy variable 3-15  3.17 
IGLV1-47 immunoglobulin lambda variable 1-47  3.10 
CXCL8 chemokine (C-X-C motif) ligand 8  3.09 
IL21 interleukin 21  3.06 
IGKV1-5 immunoglobulin kappa variable 1-5  3.06 
GNLY granulysin  3.05 
IGLC3 immunoglobulin lambda constant 3 (Kern-Oz+ marker)  3.04 
IGKV2D-24 immunoglobulin kappa variable 2D-24 (non-functional) 3.04 
IGHM immunoglobulin heavy constant mu 3.01 
IGKV3D-20 immunoglobulin kappa variable 3D-20  2.99 
IGKV3D-15 immunoglobulin kappa variable 3D-15 (gene/pseudogene) 2.98 
IGLV3-16 immunoglobulin lambda variable 3-16  2.95 
KIR2DL4 killer cell Ig-like receptor two domains long cytoplasmic tail 4  2.93 
IGLV7-43 immunoglobulin lambda variable 7-43  2.93 
IGKV1-33 immunoglobulin kappa variable 1-33  2.87 







IGLV4-69 immunoglobulin lambda variable 4-69  2.85 
CCL7 chemokine (C-C motif) ligand 7  2.84 
GZMB granzyme B  2.80 
POU2AF1 POU class 2 associating factor 1  2.76 
IGLV6-57 immunoglobulin lambda variable 6-57  2.75 
FCRL2 Fc receptor-like 2  2.75 
IGHJ6 immunoglobulin heavy joining 6  2.72 
IGLV2-11 immunoglobulin lambda variable 2-11  2.71 
BHLHA15 basic helix-loop-helix family member a15  2.71 
PTHLH parathyroid hormone-like hormone  2.69 
CNGA3 cyclic nucleotide gated channel alpha 3  2.67 
  










































































Although immunoglobulin gene expression in PTNeg lesions increased slightly 
relative to uninfected healthy skin (Figure 4C, blue), immunoglobulin gene expression in 
PTPos lesions was substantially higher (367 fold + 261 compared to 56 fold + 32) (Figure 
4C, orange). The level of immunoglobulin transcripts in the PTInt group (Figure 4B, 
yellow) fell between the PTPos and PTNeg groups (122 fold + 75). Thus, high Ig levels in 
lesions may portend a poor prognosis in this disease, as previously suggested (23). 
Immune response signatures of PTPos and PTNeg patients. An assessment of transcripts 
encoding cell-specific markers pointed to an increase in B cells and their products in the 
PTPos lesions. B cell transcripts encoding CD79A, CD19, and CD20, were upregulated in 
PTPos lesions, relative to healthy controls (Figure 5A) and relative to PTNeg lesions 
(indicated by a # symbol). Transcript levels in the PTInt group fell in between PTPos and 
PTNeg (Figure 5A, yellow). Increases in transcripts encoding B cell markers were not 
observed when comparing lesions from early and late cutaneous leishmaniasis (Figure 
6A). T cell markers (CD3e, CD4, and CD8a) demonstrated no significant differences 
between PTPos, intermediate and PTNeg lesions (Figure 5A). As expected, no significant 
differences in T cell markers were detected between early and late cutaneous lesions 
(Figure 6A). Transcripts for inflammatory molecules (IFN-γ, TNF, IL-1β and FASLG), 
inhibitory molecules (IL-10, CTLA4, PD1, PDL1, and LAG3), and activation markers 
(CD80 and CD38) were all higher in PTPos lesions compared to PTNeg lesions (Figure 4B), 
with PTInt lesions exhibiting intermediate transcript levels (Figure 5B). In contrast to the 
differences observed between PTPos and PTNeg lesions, we saw no significant difference 







Figure 5. Immune response signatures in parasite transcript positive (PTPos) and negative (PTNeg) 
lesions. (A) Bars represent the fold change of RNA expression of cell-specific markers in PTNeg (blue), 
PTInt (yellow), and PTPos (orange) samples, each compared to healthy controls (mean plus SEM). 
Statistically significant differentially expressed genes, when comparing PTPos to PTNeg are identified with a 
# symbol (p<0.05) (B) Transcripts encoding inflammatory cytokines (ifnγ, tnf, IL12p40, IL-10, faslg), anti-
inflammatory and inhibitory signals (il10, ctla4, pdcd1, cd274, lag3), and activation markers (cd80, cd38) 
in lesions of all three classifications compared to healthy controls (mean plus SEM). Statistically significant 
differentially expressed genes when comparing PTPos to PTNeg are identified with a # symbol (p<0.05). (C). 
The top module (by p-value, see * in Supplemental Figure 3A) and representative genes from within the 
module correlated to percent parasite reads using WGCNA analysis. The left plot demonstrates correlation 
to the module eigengene versus correlation to parasite percent reads for each gene. On the right, plots 
demonstrate normalized expression (rpkm) versus parasite percent reads for selected genes from within the 








Figure 6. Immune response signatures in early and late cutaneous L. braziliensis lesions. Bars 
represent the fold change (mean plus SEM) of RNA expression of cell-specific markers in early (light grey) 
and late (dark grey) cutaneous samples,, each compared to healthy patients, showing (A) infiltration of B 
cell (cd79a, cd19, cd20) and T cell (cd3e, cd4, cd8a) biomarkers, and (B) increased inflammatory 
(ifnγ, tnf, IL12p40, IL-10, faslg), anti-inflammatory and inhibitory signals (il10, ctla4, pdcd1, cd274, lag3), 









The weighted gene co-expression network analysis program (WGCNA) was used 
to cluster human host gene expression through comparison of gene expression profiles 
using pairwise correlations. Cluster profiles were then assessed as a function of parasite 
transcript abundance. This analysis yielded three modules of genes (among a total of 51 
modules in the network) whose expression exhibited a significant correlation with 
parasite transcript abundance (Figure 5B, Figure 7). The most highly correlated module 
(see * in Figure 7A) contained 100 genes (Figure 7C, left). Eight of the top 14 genes and 
their normalized expression versus parasite transcript number are shown in Figure 7C, 
right. These host genes included IL-10, IFN-γ, TNF, granzyme B and fas ligand. All of 
the genes in this module exhibited a higher expression in PTpos lesions (Figure 5C, orange 
dots). The two additional modules that also showed a significant correlation between host 
gene expression and parasite transcript numbers contained immunoglobulin transcripts, 








Figure 7. Weighted gene co-expression network analysis as a function of parasite transcript reads. 
(A) Heatmap comparing the module eigengene relationship to the trait of percent parasite reads. Heatmap 
color indicates correlations of -1 (blue) to +1 (red) and p-values are shown in parentheses. Modules are 
sorted top to bottom by significance and a different color block represents each module. The three most 
significant modules are indicated in red type with the most significant module, indicated by a *, which is 
explored further in Figure 5C. (B) The second (light yellow, top) and third (cyan, bottom) module (by p-
value) and representative genes from within the module correlated to percent parasite reads using WGCNA 
analysis. The left plots demonstrate module membership versus correlation to parasite percent reads for 
each gene. On the right, plots demonstrate normalized expression (rpkm) versus parasite percent reads for 








Functional interactions and distinct clustering among differentially expressed genes. 
The Reactome FI plugin for Cytoscape was used to observe known interactions between 
the 719 genes that were differentially expressed between PTNeg and PTPos. An additional 
149 linker genes, known to influence or connect multiple genes in the gene set, were 
included in this analysis. A network of 558 genes generated numerous clusters showing a 
dense interaction of genes differentially expressed between PTNeg and PTPos. When 
clustering genes by functional interactions from the Reactome database, the top three 
clusters highlight specific immune and cellular pathways (Figure 8). The largest cluster 
(Figure 8, blue nodes) consists of 137 genes associated with immune cell activation, 
costimulation, and cytokine and chemokine signaling, including TNF, IL-10, and 
multiple C-C motif chemokines (Figure 9A). Gene regulation in this category is 
associated with NF-κβ, CREB/STAT3, JUN, and SP1 signaling. The second largest 
cluster (Figure 8, red nodes) includes 103 genes involved in B and T cell activation and 
inhibition, regulated by SYK, SRC, FYN, PLCG1 and 2, and PTPN11 (Figure 9B). 
Cluster 3 (Figure 8, yellow nodes) includes 72 genes associated with cell growth and 
proliferation signals (Figure 9C). The transcriptomic differences between PTPos and PTNeg 
patients demonstrate the potential of these clusters to lead to the identification of new 








Figure 8. Functional interactions among differentially expressed genes. A group of 237 of the 719 
differentially expressed genes between PTNeg and PTPos (circular nodes) along with 75 associated linker 
genes (diamond nodes, black border) show numerous functional interactions (edges). Node size is relative 
to the number of interactions. The three largest gene clusters are depicted by color (blue, red, and yellow), 
and direction of differential expression of genes within the clusters is depicted by node border, with green 










Figure 9. Three largest functional interaction groups in PT-pos DE genes. The largest three clusters 
consisting of 137 (A), 103 (B), and 72 (C) genes show numerous functional interactions (edges). Gene 
clusters are depicted by color and direction of differential expression is depicted by node border, with green 
borders designating upregulated and red borders designating downregulated genes. Node size indicates the 
number of interactions. (A) Network of genes associated with immune cell activation, costimulation, and 
cytokine and chemokine signaling, including TNF, IL-10, and multiple C-C motif chemokines regulated by 
NFκβ, CREB/STAT3, JUN, and SP1 signaling. (B) Network of 103 genes involved in B and T cell 
activation and inhibition, regulated by SYK, SRC, FYN, PLCG1 and 2, and PTPN11. (C) Interaction of 72 








Identification of L. braziliensis transcripts in lesions. We analyzed parasite gene 
expression in the six PTPos patient samples and despite substantial differences in lesion 
size and duration (three early and three late cutaneous PTPos lesions), there was 
uniformity in L. braziliensis transcript expression in all six patient lesions. Pearson 
correlation analysis of the top 50 parasite genes in each sample quantitatively 
demonstrated the similarity between samples, and ranged from 0.83 to 0.92 (Figure 10A). 
The 40 most highly-expressed parasite transcripts by average RPKM, listed in Table 6, 
were fairly randomly dispersed across the different parasite chromosomes (Figure 11). 
Six of these chromosomes are illustrated in Figure 10B and the parasite gene expression 
(in RPKM) is shown by vertical lines in the 6 patients (each patient designated by a 
different color intensity). Again, there is remarkable uniformity in parasite gene 
expression from patient to patient. Within these six chromosomes, 12 of the top 20 
parasite genes (by RPKM) are noted, including cysteine peptidases, cysteine synthase, a 
proteasome subunit, and various hydrolase-like and hypothetical proteins. 
All 20 of the most highly expressed parasite genes were expressed in all six 
patients, regardless of whether the lesions were early or late (Figure 11). The top parasite 
transcripts (Table 6) consisted of a cysteine peptidase, a phosphodiesterase, as well as 
kinases and transport proteins. The presence of hypothetical proteins in this list illustrates 
our lack of understanding of parasite gene expression during natural infections. Several 
amastin family genes and known virulence factors, including GP63, heat-shock proteins 








Figure 10. L. braziliensis gene expression in human lesions. RPKM values of all samples were scaled to 
the sample with the highest total normalized reads. (A) Pearson correlation of parasite gene expression of 
the top 50 parasite genes in the six PTPos samples. (B) Representation of six parasite chromosomes (16, 21, 
28, 29, 33, 35) showing the RPKM levels for each PTPos patient, early patients depicted in pink hues, late 
patients in purple hues. RPKM is depicted on the y axis (0 to 50,000), and genes that appear in the 20 most-
highly expressed parasite genes are labeled. 








Figure 11. Circos plot of L. braziliensis genome. Representation of the L. braziliensis genome with the 
outermost ring (labeled 1–35) showing each individual chromosome. The subsequent concentric circles 
represent each of the six Vertical lines designate the relative expression levels of L. braziliensis gene 
expression in RPKM with the top 20 most highly-expressed genes marked by a red line, and numbered 








Table 6. Top 40 L. braziliensis genes expressed in detectable-positive lesions 
ID Description L. braziliensis RPKM 
LbrM.08.1060 amastin-like	protein 38297 
LbrM.08.0300 amastin-like	surface	protein,	putative 12211 
LbrM.08.1130 amastin-like	surface	protein,	putative 11338 
LbrM.18.0460 amastin-like	surface	protein 7271 
LbrM.08.0310 amastin-like	surface	protein,	putative 7125 
LbrM.08.0290 amastin-like	surface	protein,	putative 6529 
LbrM.09.1400 histone	H2B 6390 
LbrM.08.1100 amastin-like	protein 6164 
LbrM.20.4300 amastin-like	surface	protein,	putative 5869 
LbrM.20.1090 kinesin,	putative	(pseudogene) 5014 
LbrM.08.1030 amastin-like	protein 3868 
LbrM.18.1510 histone	H1 3827 
LbrM.20.0790 amastin-like	surface	protein,	putative 3779 
LbrM.20.3230 hypothetical	protein,	conserved 3753 
LbrM.08.0670 amastin-like	protein 3727 
LbrM.28.2990 heat-shock	protein	hsp70,	putative 3676 
LbrM.21.2150 beta	tubulin 3620 
LbrM.18.0470 amastin-like	surface	protein 3567 
LbrM.21.1140 histone	H2A 3342 



























Recent work by our lab demonstrated the benefits of dual-transcriptomic analyses, 
using in vitro infection of macrophages with L. major and L. amazonensis to observe 
expression pattern changes in the host cell and parasite gene expression, ranging from 4 
to 72 hours (171). To determine whether the L. braziliensis transcripts identified in 
lesions were the most highly expressed parasite genes expressed in vitro, we compared 
the top 10% of L. braziliensis transcripts identified in lesions (ranked by RPKM) to 
single reciprocal orthologous genes expressed by L. amazonensis or L. major 72 hours 
after an in vitro infection of human macrophages, as previously described by our lab 
(Figure 12). A direct comparison to L. braziliensis genes expressed in vitro was not 
possible because RNA-seq analysis of L. braziliensis transcripts following in vitro 
infection of human macrophages has not been performed.  
A comparison of single reciprocal orthologs showed that of the most highly 
expressed (top 10%) L. braziliensis genes in vivo (Figure 12A, blue), roughly 35% (155) 
did not match the most highly expressed parasite genes in cultivated macrophages 
following in vitro infection with L. amazonensis (Figure 12A, red) or L. major (Figure 
12A, green). In contrast, 35% (155) of the top genes expressed by L. braziliensis during 
in vivo infections matched the top L. major and L. amazonensis genes expressed in vitro. 
The remaining 30% of top genes expressed by L. braziliensis during in vivo infections 
were shared relatively evenly between either L. major (64) or L. amazonensis (57). 
Among all single reciprocal orthologs (6707), pearson correlation between samples 
ranged from 0.61 to 0.98 and samples hierarchically clustered into their respective groups 








Figure 12. Parasite ortholog comparisons reveal similarities and differences (A) A Venn diagram 
compares the single reciprocal orthologs expressed in the top 10% (by average RPKM) of L. braziliensis in 
patients (blue circle), L. major in macrophages (green circle), and L. amazonensis in macrophages (red 
circle). (B) Pearson correlations between samples of L. braziliensis in patients (blue), L. major in 
macrophages (green), and L. amazonensis in macrophages (red) ranges from 0.62 to 0.98. Hierarchical 
clustering is demonstrated by dendrograms.   
L. amazonensis (72hrs)


































































































































  By applying RNA-seq technology to skin biopsy material, we were able to 
capture in detail the transcriptomes of both the parasite and the human host during L. 
braziliensis localized cutaneous infection. This analysis allowed us to examine host 
responses as a function of parasite persistence. L. braziliensis infections have often been 
described as having low parasite numbers in lesions (172). This is consistent with our 
observation that lesions from 10 of the 25 patients had no detectable parasite transcripts 
in them at the time of biopsy. This lack of detectable transcripts is consistent with an 
active elimination of parasites by the host. In contrast, six of the 25 patients had ample 
evidence of high confidence parasite transcripts in lesions (averaging nearly 1M parasite 
reads/sample). The presence of these transcripts indicates that viable parasites were 
persisting in lesions, and continuing to produce transcripts that could contribute to their 
survival. Therefore, we compared host immune responses in lesions where parasites were 
producing detectable transcripts (PTPos) to those where parasite transcripts were 
undetectable (PTNeg). 
 The progression of L. braziliensis disease has been well-studied, and the small 
nodules of early tegumentary leishmaniasis typically progress to the larger sometimes 
necrotic lesions associated with late cutaneous leishmaniasis (173). Studies have 
examined the differences in immune responses between these two groups (174), and 
comparisons with regard to treatment efficacy between early and late disease have also 
been made (108, 172). A surprising result from the previous transcriptomic comparison 
between early and late L. braziliensis lesions was that the host immune response was 







Our RNA-seq confirms this previous observation. We could not separate the host 
response during early and late tegumentary leishmaniasis by Principal Component 
Analysis (Figure 2). However, when these responses were stratified by the presence or 
absence of parasite transcripts, a clear separation could be achieved between the host 
responses in lesions where parasite transcripts were detectable (PTpos) versus those where 
they were not detectable (PTneg). We chose to contrast those two groups with an eye to 
understanding host responses that may be associated with parasite persistence or parasite 
elimination.  
 One of the surprising observations from this work was the degree to which B cell 
transcripts were associated with lesions containing detectable levels of parasite 
transcripts. Of the top 100 genes that were differentially upregulated in PTPos lesions 
relative to healthy controls, 80 encoded immunoglobulin-related transcripts. Lesions in 
which parasite transcripts were not detectable (PTNeg) also showed some evidence of B 
cell activation, but not to the same extent. The quantity of immunoglobulin transcripts in 
PTPos lesions was higher than PTNeg lesions (Figure 3C), as were the number of B cells as 
judged by transcripts encoding CD79A, CD19, and CD20 (Figure 4A). We previously 
reported that in human visceral leishmaniasis, high levels of IgG were associated with 
ongoing disease, and that IgG levels decreased as cell mediated immunity developed 
following treatment (60). Furthermore, addition of parasite-specific IgG to L. major-
infected JH mice exacerbated disease, increasing lesion size and inducing IL-10 
production (60). These previously published observations, along with the present 
association of high immunoglobulin transcripts in PTPos lesions, suggest that B cells and 







 We and others previously demonstrated that IL-10 could contribute to parasite 
survival, and a correlation between IgG levels and IL-10 production was identified in 
visceral leishmaniasis (60, 175). The present studies extend this correlation to American 
tegumentary leishmaniasis, and demonstrate that PTpos lesions had higher levels of IL-10 
than PTNeg lesions (Figure 4B). The association between parasite survival and cytokine 
production may be more complex than originally perceived, however, since PTPos lesions 
also expressed higher levels of IFN-γ and TNF, two cytokines that have well-established 
roles in classical macrophage activation and parasite elimination.  
We also observed a correlation between the prevalence of parasite transcripts in 
the lesion and the expression of a subset of host immune response genes. Using the 
weighted gene co-expression network analysis program (WGCNA), we identified several 
key host response genes whose expression increased in lesions containing high levels of 
parasite transcripts (Figure 4C). IL-10 has been previously associated with disease 
progression, so perhaps its inclusion in this category may not have been unexpected. 
However, the association of TNF, granzyme B, and IFN-γ with parasite persistence was 
not expected. These observations may indicate that immunopathology is a driving factor 
in L. braziliensis infections. The second and third most significant modules (Figure 8B) 
correlate with several genes involved in B cell responses, immunoglobulin production 
and T cell interactions with parasite transcriptional activity. These observations are 
consistent with the hypothesis that B cells and IgG production may contribute to parasite 
survival.  
In addition to an in depth look at the host response, RNA-seq also provides a 







within the lesion provided some interesting surprises. First and foremost, the uniformity 
of parasite gene expression across all six patients was not expected, given the differences 
in lesion size, duration, and degree of necrosis among the six patients analyzed. It is 
possible that the most highly expressed parasite genes in lesions have the potential to 
contribute to parasite persistence. The identification of these gene products may lead to 
new candidates for vaccine development or new targets for diagnosis. In addition to the 
presence of known virulence factors expressed at a high level, 4 of the 100 most highly 
expressed parasite genes encode “hypothetical proteins” of unknown function. The 
identification and characterization of these proteins may shed new light on how this 
parasite establishes infection, persists within mammalian cells, or escapes these cells to 
spread disease. We tested whether the parasite transcripts detected in vivo were a 
reflection of the most abundant transcripts expressed by amastigotes growing in human 
macrophages in vitro. Whole transcriptome gene expression by average RPKM was 
relatively highly correlated between species and conditions (Figure 12B). However, the 
top 10% of transcripts detected in lesions were different from the top 10% transcripts 
expressed in vitro, exhibiting just a 35% overlap between L. braziliensis gene expression 
in lesions and L. major and L. amazonensis gene expression in cultivated macrophages 
(Figure 12A). Although the parasite species and time post-infection may confound these 
findings, we believe that a contrast of the Leishmania genes expressed in vivo versus in 
vitro provides a useful baseline for future comparisons. This suggests that the transcripts 
identified in L. braziliensis lesions were not simply the most highly expressed 
leishmanial genes, but rather might be transcripts specific to parasite survival under 








Chapter 4: Meta-transcriptome profiling of the anergic diffuse 
cutaneous human-Leishmania amazonensis lesion 
ABSTRACT 
  Diffuse cutaneous leishmaniasis (DCL) is a rare form of cutaneous leishmaniasis 
where parasites grow uncontrolled in diffuse lesions across the skin. We used high 
throughput RNA-seq to simultaneously analyze human and parasite gene expression in 
Leishmania amazonensis-infected patients with diffuse cutaneous leishmaniasis. 
Transcripts in biopsies from six patients with DCL were sequenced, and results were 
compared to previously analyzed biopsies taken from localized cutaneous leishmaniasis 
(LCL). Meta-transcriptomic analysis demonstrated an increased infiltration of atypical B 
cells producing high levels of immunoglobulin transcripts including a preponderance of 
the IgG4 isotype, and variable region gene patterns consistent with an oligoclonal 
antibody response. DCL lesions contained a reduced number of CD8+ T cells and a 
marked reduction in transcripts encoding perforin, granzyme, and granulysin. The 
commonly used designation of ‘anergic DCL’ that is sometimes associated with this 
disease was not manifested in reduced CD4 T cell numbers nor in an upregulation of 
markers of T cell anergy. The number of pan-macrophage transcripts in DCL was similar 
to those observed in the more common localized cutaneous leishmaniasis (LCL), but 
alterations in macrophage activation state markers were observed in DCL. Whereas 
classically activated macrophages dominated localized disease, exhibiting high levels of 
M1 transcripts for IDO1, iNOS, CXCL9, CXCL10, CXCL11, IL6, TNFα, macrophages 
in DCL exhibited a regulatory phenotype with reduced levels of the M1-associated 







localized or diffuse disease exhibited signs of Th2 responses or alternative macrophage 
activation. The high levels of parasite transcripts in DCL afforded a unique opportunity to 
study parasite gene expression in diffuse disease. Parasite transcription displayed 
remarkable uniformity among the six patients despite differences in infection duration 
and patient age. We identified the transcripts most highly expressed in DCL and utilized 
published datasets to uncover subsets of highly expressed genes common to multiple 
Leishmania species. Over half of these genes were hypothetical proteins, emphasizing the 
need for further research to annotate the parasite genomes. In summary, RNA-seq 
allowed us to fully examine host and parasite responses in diffuse cutaneous 
leishmaniasis lesions and determine factors that define the variation in disease 
manifestation of leishmaniasis.  
INTRODUCTION 
As previously discussed, parasitic Leishmania spp cause the spectral disease 
leishmaniasis, ranging from self-healing cutaneous lesions to a visceral and highly fatal 
form of disease (72, 74). Manifestations of cutaneous leishmaniasis depend highly on 
parasite species and host immune responses. Tegumentary leishmaniasis caused by 
Leishmania braziliensis infections typically result in a single dermal lesion, with small 
numbers of parasites and a strong host delayed-type hypersensitivity (DTH) response (90, 
103). Roughly 3-5% of these infections can progress to a disfiguring mucocutaneous 
disease (161). The L. amazonensis species can also cause cutaneous disease, but in 
contrast to L. braziliensis, can manifest as diffuse cutaneous leishmaniasis (DCL). In this 
rare form of the disease, parasites grow uncontrolled in non-ulcerative lesions diffuse 







refractory to chemotherapy (176). While the morphology and pathology of diffuse 
cutaneous lesions has been studied, the underlying causes are not as well understood.  
Leishmaniasis can be considered a macrophage-mediated disease because 
macrophages act as the primary host cells in which the parasites reside and replicate. 
During infection, murine macrophages undergo transcriptional and morphological 
changes that allow for parasite survival, including inhibited iNOS, TNF-α, and IL-12 in 
concert with increases in IL-10, Arginase I, PGE2, and TGF-β expression (135). 
Research in mice demonstrates a clear role for Th1 responses, and implicates IFN-γ, 
TNF-α, and iNOS in parasite clearance. Conversely, Th2 responses (IL-4, IL-13) are 
associated with parasite persistence and disease exacerbation in the mouse (177, 178). A 
similar dichotomy has not been observed in humans. Whereas inflammatory Th1 markers 
have been associated with a restriction of parasite replication (72), the search for Th2 and 
specifically downstream alternative macrophage activation markers has been less 
successful (71). Our previous research (179) and that of our colleagues (48) observed a 
significant Th1 response in localized American tegumentary leishmaniasis. In this work, 
we aim to expand this knowledge and assess host and parasite responses in the diffuse 
form of the disease.  
Diffuse cutaneous leishmaniasis was first catalogued in the mid-20th century 
characterized as lesions disseminated over the body, high parasite burden, negative skin 
tests, and unresponsiveness to antimony therapies (180). The causative parasite in Brazil 
is L. amazonensis (121, 181) and lesion infiltrates have previously been identified as 
mostly macrophage, with limited and rare lymphocyte or plasma cell presence (182–185). 







dominant response in lesions (121). High levels of serum IgG specific to Leishmania 
have also been observed (122, 123), but whether they were simply a result of high 
parasite burden or actively contributed to disease pathology could not be determined. 
DCL has been termed “anergic” DCL, primarily due to the lack of DTH+ responses in 
DCL patients (186).  
In the previous chapter, data from human LCL lesions highlighted specific cell 
populations and activation states within lesions. (179). We hypothesize that the host 
immune response in localized lesions resides at the opposite end of the leishmaniasis 
disease spectrum (74), highlighting the need for in-depth analyses of diffuse cutaneous 
lesions. Incorporating previous analyses, we sequenced and analyzed the host and 
parasite transcriptomes in L. amazonensis-infected DCL patients and report dramatic 
similarities and differences between these diverging manifestations.  
RESULTS 
The human host transcriptome in L. amazonensis-infected DCL patients. RNA-seq 
was performed on biopsies from six DCL patients infected with Leishmania amazonensis. 
The age of the five male and 1 female patients ranged from 15 to 50, and the duration of 
illness ranged from 14 to 35 years (Table 2). Host responses to the infection were similar 
among all 6 patients and markedly different from LCL infections (Figure 13A, D, E), 
with Pearson Correlations generally being 0.70 or higher between all but one of the DCL 
patients (Patient #5, Figure 13B) despite substantial differences in age (Figure 13C) and 








Figure 13. The human host transcriptome in L. amazonensis-infected DCL patients (A) 
A principle component analysis plot demonstrates whole-transcriptome differences between healthy (grey), 
LCL (blue), and DCL (red). (B) PCA analysis shows the age of the DCL patients on a color scale (red to 
blue). Principal component 1 represents 40.98% of the variance and principle component 2 represents 
24.97%. (C) PCA analysis shows the illness duration of the DCL patients on a color scale (red to blue). 
Principal component 1 represents 40.98% of the variance and principle component 2 represents 24.97%. 
(D-E) Venn diagrams show up (E) and downregulated (F) genes in DCL (red) and LCL (blue) circles 
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Differential expression comparisons with healthy patients (fold change > 2, p-value < 
0.05) revealed 2420 host genes upregulated (Figure 13E) and 2846 genes downregulated 
(Figure 13F) (fold change > 2, p-value < 0.05) as compared to healthy skin. Previously 
sequenced LCL patients showed an upregulation of 2384 genes and a downregulation of 
2685 genes (Figure 13E-F). DCL and LCL differential expression shared 1485 
upregulated and 1475 downregulated genes.  
An examination of host transcripts in the lesion pointed to two unusual aspects of 
the host immune response to this intracellular parasite. The first was the high level of 
transcripts encoding immunoglobulin fragments and the second was the paucity of 
transcripts that would likely be expressed by cytotoxic T cells. Compared to healthy skin, 
the top 10 most highly upregulated host transcripts in all six patient biopsies encoded 
immunoglobulin fragments (Figure 14A). In fact 90 of the top 100 most highly 
upregulated transcripts in lesions were immunoglobulin transcripts, and four of the other 
top 100 transcripts were related to B cells. This enrichment of Ig transcripts was common 
to all six patients, and there was a high degree of consensus among the individual Ig 
RPKMs (Figure 14A, triangles). Due to the mass upregulation of immunoglobulin 
transcripts, we subsequently analyzed immunoglobulin isotype gene usage and noted 
significant differences in Ig levels in DCL patient lesions relative to healthy controls and 
LCL lesions (Figure 14B). DCL patients expressed high levels of IgG1, IgG2, IgG3 and 
IgG4 with IgG4 unexpectedly accounting for an average of 40% of the immunoglobulin 
repertoire (Figure 14B). LCL patients exhibited lower levels of all immunoglobulin 








Figure 14. IgG4 transcripts are significantly upregulated in DCL lesions (A) Bars show the mean 
RPKM for the top ten upregulated genes (mean plus SEM), with each individual sample represented by a 
black triangle. (B) Bars represent the expression (RPKM mean plus SEM) for each immunoglobulin 
isotype in healthy skin (black), LCL lesions (blue), and DCL lesions (red). (C) Immunoglobulin isotype 
frequency analysis of healthy skin (black bars), LCL (blue bars) and DCL (red bars) is shown as mean plus 
SEM. Significant differences compared to healthy skin are marked with a * while significant differences 




































































































































































































IgG4 levels in LCL were not different from uninfected controls. Analysis of isotype 
frequency emphasized the dominance of IgG4 in DCL lesions (Figure 14C). Subsequent 
staining of DCL lesions with IgG4 antibody revealed high levels of this isotype (Figure 
14D).  
In addition to upregulated immunoglobulin transcripts, a marked increase in B 
cell-related transcripts was observed in DCL lesions compared to both healthy skin and 
LCL lesions. The upregulation of B cell-related markers, including MZB1, CD79A, 
TNFRSF17, CD22, CD27, CD19, CD79b, BAFF, and APRIL, were observed in lesions 
from DCL patients (Figure 15A). Histology from diffuse lesions confirm these findings, 
with B cells expressing CD19 (Figure 15B) in DCL. 
Using MiXCR and the bioconductor package bcRep, we observed an enrichment 
of specific V-J combinations and V gene usage demonstrative of an oligoclonal response 
in DCL patient lesions. A chord diagram of average heavy chain V-J combination 
frequency in DCL patients demonstrated a specific immunoglobulin gene selection 
response limited to 25% of IGHV genes used at a frequency greater than 1% (Figure 16).  
We also observed differences in V gene usage between DCL and LCL lesions. 
The prominent heavy V gene subgroups present in DCL and LCL patients were IGHV1, 
IGHV3 and IGHV4 (Figure 17A). However, each of these V gene subgroup frequencies 
differed between LCL and DCL, with LCL using higher frequency of IGHV3 and DCL 
employing higher usage of IGHV1 and IGHV4. Light chain kappa V gene subgroup 
usage was composed mostly of IGKV1, IGKV1D, IGKV3, and IGKV3D, while lambda 
V gene subgroup usage was mainly restricted to IGLV1, IGLV2, and IGLV3 (Figure 17B 















Figure 15. B cell transcripts are significantly upregulated in DCL lesions (A) Bars represent log2 fold-
changes of B cell markers (mzb1, cd79a, tnfrsf17, cd22, cd27, cd79b) in LCL (blue) and DCL (red) 
compared to healthy skin (fold change ≥ 2, p<0.05). Significant differences between LCL and DCL are 





































































Figure 16. Immunoglobulin repertoires in DCL patients are oligoclonal (1G) A representative chord 
diagram shows average V and J gene usage (width of gene arc) and combination frequency in DCL patients 








Figure 17. Skewed immunoglobulin V gene and subgroup usage in DCL and LCL lesions. Heavy and 
light chain V gene subgroup and gene usage frequency shows differences and similarities in LCL (blue 
bars, n=6) and DCL (red bars, n=6) host immunoglobulin responses. Only 6 of the LCL lesions contained 
enough immunoglobulin transcripts for a meaningful analysis. (A, C, E) Bar graphs show V gene subgroup 
usage in heavy, kappa, and lambda chains. (B, D, F) Bar graphs show V gene usage in heavy, kappa, and 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Both kappa and lambda subgroup frequencies contained differences between LCL and 
DCL. Heavy and light chain V gene usage was skewed in both LCL and DCL, as 
expected. Among heavy chain V genes, more than 90% of transcripts mapped to just 29 
genes (34%) (Figure 17D). In the same manner, kappa light chain V gene usage consisted 
mainly of 24 genes, with IGKV1-5 as the most used kappa V gene (>12%) (Figure 17E). 
Lastly, lambda light chain V gene usage was limited to 18 genes, all of which made up 
more than 92% of lambda light chain V gene transcripts, with IGLV2-14 as the most used 
lambda gene (>27%) (Figure 17F). While most of the V gene usage was comparable 
between DCL and LCL lesions, nine heavy chain, two kappa light chain, and three 
lambda light chain V genes exhibited significant differences between the two 
manifestations of disease (Figure 17, designated *).  
Altered cytotoxic T cell responses in DCL lesions. We examined T cell responses in 
DCL lesions and compared them to healthy controls and lesions from 25 LCL patients 
previously analyzed (179). DCL and LCL patients expressed similar levels of transcripts 
for CD4 and CD132 (IL2Rg) (Figure 18A, designated ns), but DCL lesions contained 
lower transcript levels for all three CD3 chains, CD127 (IL-7r), and zap70 (Figure 18A). 
DCL also expressed reduced transcripts for the Th1 transcription factor tbet, but similar 
levels for gata3, foxp3, and rorc (Figure 18A). Cytokine transcripts were also measured 
in DCL lesions. There was a significant reduction in the Th1-associated transcripts for 
IFNγ and TNF in DCL lesions, relative to LCL. There was no evidence for a Th2 
response in DCL, as transcript levels for IL-4, IL5, and IL-13 were not different from 







Figure 18. Reduced cytotoxic T cell responses in DCL lesions (A) Bars represent the log2 fold-change of 
generic T cell markers and transcription factors in LCL (blue) and DCL (red) patients (mean plus sem, p < 
0.05). Differences between LCL and DCL are indicated (*p-value < 0.05, ns = not significant). (B) Bars 
show average RPKM values (plus SEM) for healthy (black), LCL (blue), and DCL (red) for various 
cytokines involved in Th1 (ifng, tnf, lta, il1b, il2), Th2 (tgfb1, il4, il5, il9, il10, il13, il21, il31), and Th17 
(il17a) responses. Significant differences versus healthy (#, p-value < 0.05) and between LCL and DCL (*, 
p-value < 0.05) are indicated. (C) Bars show mean RPKM values (plus SEM) for healthy (black), LCL 
(blue), and DCL (red) for CD8 and cytotoxic T lymphocyte effector molecules. All transcripts in LCL and 
DCL were significantly upregulated versus healthy. Significant differences between LCL and DCL are 
indicated (*, p-value < 0.05). (D) Bars represent the log2 fold-change of T cell activation and inhibition 
markers in LCL (blue) and DCL (red) patients (mean plus sem, p < 0.05). Differences between LCL and 



































































































































































































































































There was a significant reduction in CD8A transcripts in DCL lesions relative to 
healthy controls and LCL (Figure 18C). Transcripts for cytotoxic effector molecules, 
including granulysin, granzyme A, granzyme B, and perforin, were also significantly 
diminished in DCL lesions compared to LCL (Figure 18C). 
 Various markers of T cell activation, including transcripts for CD28, OX40, 
GITR, CD137, CD69, and CD40L, were decreased in DCL relative to LCL (Figure 18D). 
The expression of inhibitory signaling molecules indicative of anergy, including PD-1, 
BTLA, and LAG3, was also significantly lower in DCL.  
Contrasting macrophage activation states in DCL and LCL lesions. Both DCL and 
LCL lesions have a significant upregulation of pan-macrophage markers compared to 
healthy skin, and there appears to be no significant difference between the two disease 
states regarding the presence of macrophages. Comparable expression of genes generally 
expressed on macrophages, including FCGR1A, FCGR1B, SIGLEC1, CD11b, CD18, 
CD204, CD209, and CD68, was observed in LCL and DCL with only minor differences 
between diseases (Figure 19A, designated ns). However, markers of macrophage 
activation states were significantly different between DCL and LCL.  
Data from a separate project in our lab found that LPS-stimulated macrophages 
(so-called M1) upregulated 2017 genes (data not shown). Of those, 487 genes were 
expressed significantly higher in LCL compared to DCL (not shown). Figure 19B shows 
the ten most highly upregulated transcripts in M1 macrophages, nine of which were 
significantly higher in LCL (blue bars) relative to DCL (red bars). One of the surprising 
exceptions to this was IL-12β, which is similarly expressed in LCL and DCL lesions 









Figure 19. Altered macrophage responses in DCL lesions exhibit regulatory characteristics (A-C) 
Fold-changes of pan-macrophage markers (A), classically activated macrophage markers (B), and anti-
inflammatory macrophage markers (C) in LCL (blue) and DCL (red) compared to healthy skin. Differences 
between LCL and DCL lesions are shown (ns = not significant, * = significant, fold-change ≥ 2, p < 0.05). 
































































































































































In a separate project, we demonstrated that human macrophages stimulated with 
LPS plus immune complexes assume a regulatory phenotype (R-MΦ) (manuscript in 
preparation). These R-Mϕ differ from LPS stimulation by downregulating inflammatory 
genes and upregulating anti-inflammatory and growth factor genes. Analysis of data from 
this project revealed an upregulation of 925 genes and a downregulation of 632 genes in 
R-MΦ compared to LPS (data not shown). Due to the overwhelming upregulation of 
immunoglobulin in DCL lesions, we hypothesized that R-MΦ would be present in these 
lesions.  
Among the upregulated genes in R-MΦ, 90 showed significantly higher 
expression in DCL compared to LCL. DCL and regulatory macrophages similarly 
upregulated genes that included ABCB5, DCSTAMP, SPP1, SLAMF9, MTRNR2L8, 
and MMP19 (Figure 19C). A marker of marginal zone (MZ) macrophages (MARCO) 
was also expressed significantly higher in DCL compared to LCL (Figure 19C). 
Histology confirmed the presence of DCSTAMP in DCL lesions (Figure 19D). Of note, 
the anti-inflammatory cytokine IL-10 was unexpectedly equally upregulated in LCL and 
DCL (Figure 19C). Among the more than 600 downregulated genes in R-MΦ, 148 were 
downregulated in DCL compared to LCL, indicative of a downregulation of 
inflammatory responses seen in classical activation. 
Effectors of alternative activation (so-called M2a), including IL-4, IL-5, IL-13, 
were expressed at low or undetectable levels in LCL and DCL lesions (Figure 18B). 
Markers and chemokines known to identify or influence Th2 or M2a responses were also 
lowly expressed, including the chemokine and cytokine receptors CCR3, CCR4, CCR8, 








Figure 20. Minimal Th2/M2a responses in LCL and DCL lesions (A) Bars show log2 fold-changes of 
various Th2 and M2a markers and effector molecules. Of 26, 14 were upregulated in LCL (blue), 13 in 
DCL (red), 2 downregulated in LCL, and 2 downregulated in DCL. Only 5 demonstrated significant 
differences between LCL and DCL (CCR4, IRF4, FGL2, CCL14, CCL26). (B) Bars show RPKMs for each 

































































































































































































L. amazonensis gene expression in DCL lesions. Metatranscriptomic analysis revealed 
that a high percentage (10-30%) of the transcripts in DCL lesions mapped to the L. 
amazonensis genome (Figure 21A, red bars). In contrast, the percentage of reads that 
mapped to the L. braziliensis genome in LCL was below 2% (Figure 21A, blue bars). 
Parasite transcription in diffuse lesions displayed a high degree of patient-to-patient 
uniformity (Figure 21B). The top transcripts expressed by parasites in lesions consisted 
mainly of ribosomal and histone proteins, but did contain some hypothetical proteins and 
the known virulence factor kinetoplastid membrane protein-11 (Table 7). A deeper look 
at the top 500 expressed genes (data not shown) revealed 183 hypothetical proteins 
(>35%) as well as multiple predicted or known peptidases and heat shock proteins. 
We reasoned that the deficiency in Th1 immune responses in DCL would result in 
lesion macrophages that were as susceptible to infection as tissue-cultured macrophages 
infected in vitro in the absence of T cells. We therefore compared the L. amazonensis 
transcripts in diffuse lesions to that of previously analyzed L. amazonensis transcripts 
produced during in vitro infection of human macrophages (72 hours). After ranking genes 
by average RPKM, we observed a general trend of similar parasite gene expression 
(Figure 21C). Roughly 75% of genes (~6300) were ranked within a margin of 20% of 
each other when comparing DCL to in vitro infection (Figure 21C, shaded region). 









Figure 21. L. amazonensis expression in DCL lesions (A) Bars represent the percent of reads that mapped 
to parasite genomes in DCL (red) and LCL (blue). (B) Bars represent RPKMs for the top 15 genes 
expressed by L. amazonensis in 6 DCL patients. (C) A scatter plot visualizes the similarity in parasite gene 
expression between DCL L. amazonensis infections (x-axis) and in vitro L. amazonensis infection of 
macrophages (y-axis). Genes were ranked by average RPKM in DCL (n=6) and in vitro infection of 








Table 7. Top 40 genes by RPKM expressed by L. amazonensis in DCL lesions 
ID Description Average RPKM 
LmxM.27.1240 histone H1, putative 14245 
LmxM.34.0240 60S ribosomal protein L30 13205 
LmxM.28.2205 ribosomal protein S29, putative 13167 
LmxM.08_29.2370 60S ribosomal protein L39, putative 9960 
LmxM.27.1190 histone H1, putative 9566 
LmxM.01.0410 hypothetical protein 8612 
LmxM.15.0010 histone H4 8378 
LmxM.30.0900 hypothetical protein, conserved 8114 
LmxM.27.0130 hypothetical protein, conserved 8054 
LmxM.34.2221 kinetoplastid membrane protein-11 8051 
LmxM.29.0670 40S ribosomal protein S30, putative 7923 
LmxM.36.3750 40S ribosomal protein S27-1, putative 7597 
LmxM.24.2050 60S ribosomal protein L26, putative 7103 
LmxM.34.2050 60S ribosomal protein L32 6641 
LmxM.36.3400 ribosomal protein L29, putative 6599 
LmxM.16.1170 60S ribosomal protein L39, putative 6345 
LmxM.21.1050 60S ribosomal protein L9, putative 6340 
LmxM.13.0570 40S ribosomal protein S12, putative 6211 
LmxM.31.2690 ribosomal protein L27, putative 6028 
LmxM.36.1925 60S ribosomal protein L37a 5938 
LmxM.26.2220 ribosomal protein L38, putative 5930 
LmxM.03.0250 ribosomal protein L38, putative 5821 
LmxM.09.1340 histone H2B 5772 
LmxM.21.1550 40S ribosomal protein S11, putative 5451 
LmxM.34.3290 60S ribosomal subunit protein L31, putative 5446 
LmxM.34.0600 60S ribosomal protein L18a, putative 5435 
LmxM.26.2330 60S ribosomal protein L35, putative 5362 
LmxM.34.1910 ribosomal protein L15, putative 5345 
LmxM.06.0580 60S ribosomal protein L23a, putative 5254 
LmxM.36.2860 40S ribosomal protein S24e 5172 
LmxM.36.2870 40S ribosomal protein S24e 5153 
LmxM.13.1670 60S ribosomal protein L44, putative 5130 
LmxM.08_29.1740 histone H2A, putative 5102 
LmxM.34.3780 60S ribosomal protein L27A/L29, putative 5090 
LmxM.31.0430 60S ribosomal protein L17, putative 5085 
LmxM.17.1220 histone H2B 5058 
LmxM.30.1170 hypothetical protein, unknown function 5048 
LmxM.36.3770 transcription factor btf3, putative 5018 
LmxM.36.3760 60S ribosomal protein L10a, putative 4985 







We further reasoned that the strong Th1 response in LCL would exert immune 
pressure on L. braziliensis parasites in lesions and alter parasite transcriptional responses. 
We therefore used previously obtained data from our lab (171, 179) and identified 6713 
single reciprocal orthologs to compare parasite transcription of in vivo L. amazonensis 
infections in DCL to in vivo L. braziliensis infections in LCL and in vitro L. major and L. 
amazonensis infections in human-cultivated macrophages (Figure 22). Pearson 
correlations demonstrated a high degree of similarity between transcripts produced by 
parasites in DCL and in vitro infections in macrophages regardless of species (Figure 
22A). The L. braziliensis parasite transcriptomes did not correlate at the same level when 
compared with the rest of the samples. We then normalized gene expression rank in the 
respective experiments to a scale of 0-1. Using this metric, we extracted 78 genes 
expressed at a higher level (difference > 0.2) by L. amazonensis in DCL, 64 of which are 
hypothetical proteins (Figure 22B). Lastly, we compared the top 10% of genes (by 
average RPKM) expressed by the parasite in each experiment, revealing 137 genes 
commonly expressed at a high level (Figure 22C). Among this subset was 72 hypothetical 
proteins and 33 proteins with at least one predicted transmembrane region (Table 8). 
Overlap between these designations was 25 hypothetical proteins with at least one 
predicted transmembrane region. We also observed multiple peptidases and oxidases that 








Figure 22. Comparisons of parasite transcriptomes in leishmaniasis and in vitro infections. 
Comparisons were made using single reciprocal orthologous genes between L. amazonensis in DCL, L. 
amazonensis during in vitro macrophage infection (72hrs), L. major during in vitro macrophage infection 
(72hrs), and L. braziliensis in LCL (A) A heatmap represents the Pearson correlation of expression 
(RPKM) between samples. Correlations range from 0.54 to 0.98. (B) Bars indicate gene rank on a scale of 
0-1 in L. amazonensis DCL (red), L. amazonensis in vitro (green), L. major in vitro (purple), and L. 
braziliensis LCL (blue). All 78 genes were expressed at a higher level (>0.2) in DCL compared to the other 
three infections. (C) A Venn diagram of the top 10% of genes expressed (by average RPKM) in L. 
amazonensis in DCL (red box, 508), L. amazonensis in vitro (green box, 443), L. major in vitro (purple 
box, 480), and L. braziliensis in LCL (blue box, 431). The highlighted 137 genes were commonly 
expressed within the top 10%.  
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Table 8. Common highly expressed Leishmania genes (top 10%)  
TM 
regions 
Description L. mexicana ID 
0 60S	ribosomal	protein	L30 LmxM.34.0240 
0 40S	ribosomal	protein	S12,	putative LmxM.13.0570 
0 hypothetical	protein,	unknown	function LmxM.30.1170 
0 ALBA-domain	protein	1 LmxM.13.0450 
0 transcription	factor	btf3,	putative LmxM.36.3770 
0 RNA-binding	protein	5,	putative LmxM.09.0060 
0 hypothetical	protein,	conserved LmxM.27.0130 
0 hypothetical	protein,	conserved LmxM.15.1520 
0 hypothetical	protein,	conserved LmxM.29.2760 
0 nuclear	RNA	binding	domain LmxM.31.0750 
4 hypothetical	protein,	unknown	function LmxM.08.0640 




0 hypothetical	protein,	conserved LmxM.09.0010 
0 nucleolar	RNA-binding	protein,	putative LmxM.07.0990 
1 hypothetical	protein,	conserved LmxM.17.0340 
1 hypothetical	protein,	conserved LmxM.27.0110 
1 cytochrome	c	oxidase	VIII	(COX	VIII),	putative LmxM.30.1570 
1 hypothetical	protein,	unknown	function LmxM.27.2150 
0 inhibitor	of	cysteine	peptidase LmxM.24.1770 
0 hypothetical	protein,	conserved LmxM.29.0770 
0 hypothetical	protein,	conserved LmxM.03.0960 
10 inosine-guanosine	transporter LmxM.36.1940 
0 hypothetical	protein,	conserved LmxM.01.0300 
0 cytochrome	c	oxidase	subunit	V,	putative LmxM.26.1710 
1 hypothetical	protein,	conserved LmxM.04.0630 




0 dynein	light	chain,	flagellar	outer	arm,	putative LmxM.31.0230 
0 hypothetical	protein,	conserved LmxM.14.0190 
0 hypothetical	protein,	conserved LmxM.22.1640 
0 cytochrome	c	oxidase	subunit	VI,	putative LmxM.21.1710 
0 protein	disulfide	isomerase	2 LmxM.36.6940 
1 cytochrome	oxidase	subunit	IX,	putative LmxM.36.6995 
0 glutaredoxin-like	protein LmxM.27.0810 
0 hypothetical	protein,	conserved LmxM.33.4010 







0 universal	minicircle	sequence	binding	protein,	putative LmxM.36.1640 
0 ubiquinol-cytochrome-c	reductase-like	protein LmxM.30.2580 
1 hypothetical	protein,	conserved LmxM.24.1330 
0 hypothetical	protein,	conserved LmxM.08.1100 
0 small	GTP-binding	protein,	putative LmxM.05.0030 
0 sm-f	snRNP	core	complex	protein,	putative LmxM.34.4460 
0 ADP-ribosylation	factor,	putative LmxM.30.2790 
0 nuclear	protein	family	a	(nop10p),	putative LmxM.36.0340 
0 histone	H3	variant	V LmxM.19.0630 
0 cyclophilin LmxM.06.0120 
0 hypothetical	protein,	conserved LmxM.36.0480 
0 hypothetical	protein,	conserved LmxM.25.0590 
0 hypothetical	protein,	conserved LmxM.34.0100 
1 hypothetical	protein,	conserved LmxM.34.0140 
1 hypothetical	protein,	conserved LmxM.29.2845 
0 phosphoprotein	lepp12 LmxM.36.5720 
0 hypothetical	protein,	conserved LmxM.36.0620 
1 hypothetical	protein,	conserved LmxM.31.3610 
0 hypothetical	protein,	conserved LmxM.23.0370 
1 hypothetical	protein,	conserved LmxM.36.1770 
0 endoribonuclease	L-PSP	(pb5),	putative LmxM.23.0200 
1 hypothetical	protein,	unknown	function LmxM.30.1190 
0 Ran-binding	protein	1,	putative LmxM.13.1480 
0 Acyl	carrier	protein,	mitochondrial,	putative LmxM.27.0290 
0 hypothetical	protein,	conserved LmxM.32.2060 
1 protein	disulfide	isomerase LmxM.06.1050 
1 hypothetical	protein,	conserved LmxM.25.2090 
0 hypothetical	protein,	conserved LmxM.05.0450 
0 fructose-1,6-bisphosphate	aldolase LmxM.36.1260 
0 kinetoplast-associated	protein	p18-2,	putative LmxM.31.3770 
1 cytochrome	oxidase	subunit	VII LmxM.25.1130 




0 hypothetical	protein,	conserved LmxM.21.0040 
0 hypothetical	protein,	conserved LmxM.31.0165 
0 elongation	factor-1	gamma LmxM.09.0970 
0 hypothetical	protein,	conserved LmxM.22.0270 
0 centrin-4,	putative LmxM.22.1410 
0 actin LmxM.04.1230 
1 hypothetical	protein,	conserved LmxM.25.0660 
0 hypothetical	protein,	conserved LmxM.17.0850 







1 hypothetical	protein,	conserved LmxM.34.1210 
0 ATP	synthase	F1	subunit	gamma	protein,	putative LmxM.21.1770 
0 glycine	cleavage	system	H	protein,	putative LmxM.34.4720 
0 hypothetical	protein,	conserved LmxM.05.1000 
0 vacuolar	ATP	synthase	subunit,	putative LmxM.12.0520 
0 Ras-related	protein	Rab4,	putative LmxM.31.0490 
0 prefoldin	subunit,	putative LmxM.05.1200 
3 hypothetical	protein,	conserved LmxM.31.2995 
0 i/6	autoantigen-like	protein LmxM.22.1460 
1 ascorbate	peroxidase,	putative LmxM.33.0070 
0 ubiquitin-conjugating	enzyme,	putative LmxM.13.1580 
0 small	nuclear	ribonucleoprotein	SmD2 LmxM.32.3190 
0 hypothetical	protein,	conserved LmxM.17.0890 
0 hypothetical	protein,	conserved LmxM.22.0680 
0 ribonuclease	mar1 LmxM.12.0060 
0 hypothetical	protein,	unknown	function LmxM.01.0690 
0 hypothetical	protein,	conserved LmxM.32.0020 
0 hypothetical	protein,	unknown	function LmxM.34.1370 
0 hypothetical	protein,	conserved LmxM.31.0630 
0 hypothetical	protein,	conserved LmxM.33.3910 
0 stress-inducible	protein	STI1	homolog LmxM.36.0070 
0 hypothetical	protein,	conserved LmxM.25.0715 
1 hypothetical	protein,	conserved LmxM.05.1030 
0 hypothetical	protein,	conserved LmxM.28.2660 
4 hypothetical	protein,	conserved LmxM.28.1120 
0 hypothetical	protein,	conserved LmxM.25.1620 
0 hypothetical	protein,	conserved LmxM.36.3370 
0 GTP-binding	protein,	putative LmxM.25.1420 
0 hypothetical	protein,	conserved LmxM.30.1580 
0 hypothetical	protein,	conserved LmxM.25.0820 
2 hypothetical	protein,	conserved LmxM.34.1840 
0 cytochrome	c1,	heme	protein,	mitochondrial,	putative LmxM.07.0060 
0 autophagocytosis	protein,	putative LmxM.32.0295 
0 hypothetical	protein,	unknown	function LmxM.24.1600 
0 profilin,	putative LmxM.31.0520 
2 hypothetical	protein,	conserved LmxM.30.1120 
0 small	nuclear	ribonucleoprotein	polypeptide	e,	putative LmxM.29.1205 
0 phosphomannomutase,	putative LmxM.36.1960 
0 nuclear	transport	factor	2,	putative LmxM.10.0850 
0 ATP	synthase,	epsilon	chain,	putative LmxM.29.3600 
0 clathrin	coat	assembly	protein	AP17,	putative LmxM.33.2330 
0 hypothetical	protein,	conserved LmxM.36.6760 







0 hypothetical	protein,	conserved LmxM.29.0830 
0 hypothetical	protein,	unknown	function LmxM.10.0450 
0 nucleolar	protein	56,	putative LmxM.10.0210 
0 metallo-peptidase,	Clan	MG,	Family	M24 LmxM.19.0160 
1 hypothetical	protein,	unknown	function LmxM.29.1390 
0 glutamine	synthetase,	putative LmxM.06.0370 
0 ATG8/AUT7/APG8/PAZ2,	putative LmxM.19.1630 
0 prefoldin	5-like	protein LmxM.22.0670 
1 hypothetical	protein,	conserved LmxM.26.1100 
0 hypothetical	protein,	conserved LmxM.36.4670 
2 hypothetical	protein,	conserved LmxM.26.0680 
0 eukaryotic	translation	initiation	factor	3	subunit	j LmxM.25.2120 
0 hypothetical	protein,	conserved LmxM.36.6345 
4 hypothetical	protein,	unknown	function LmxM.25.1880 









  The use of RNA-seq to analyze human skin biopsies from Leishmania-infected 
patients enabled a simultaneous in-depth assessment of the host and parasite 
transcriptomes. We identified a combination of host responses that correlate with the 
promotion of disease persistence in DCL lesions. Our observations highlighted a 
prominent role for B cells in progressive disease. They also pointed to a diminished 
cytotoxic T cell response and a disease-promoting, rather than restricting, macrophage 
activation state. We propose that elevated B cell presence and localized antibody 
production help to initiate a regulatory and anti-inflammatory macrophage activation 
state leading to exacerbation of infection in the diffuse state (Figure 23). 
As previously discussed, infiltration of B cells in leishmaniasis lesions is known 
and some of their contributions to disease resolution have been reported (105, 113, 114, 
187). Our previous work demonstrated correlations between parasite persistence and 
immunoglobulin production (60, 179). We now characterized the B cell response in 
human DCL, and demonstrate that immunoglobulins don’t simply associate with severe 
disease, but actually contribute to it. We also uncovered atypical features that could 
contribute to disease progression. Most strikingly, DCL lesions are dominated by IgG4 
(Figure 14), divergent from most other chronic infections (188). The IgG4 isotype does 
not bind complement or activating FcRs well (189–191). Furthermore, IgG4 binds to the 
inhibitory FcγRIIB better than other IgG isotypes (189). IgG4 has previously been 
implicated in other disease states resulting in fibroinflammatory conditions (192). 
Therefore IgG4 may contribute to the anti-inflammatory and DTH-refractory nature of 














Figure 23. Biased B cell responses and altered macrophage and T cell activation lead to DCL 
phenotypes. Domination of the immunoglobulin response by IgG4 promote anti-inflammatory phenotypes 
in infected macrophages and the surrounding microenvironment, promoting parasite survival, extracellular 
matrix remodeling, and angiogenesis. Regulatory macrophages expressing MARCO receptor augment the 
anti-inflammatory macrophage response via ERK1/2 signaling and retain plasma B cells. Increased anti-

































This anomaly in serum IgG production was reported 24 years ago in a small number of 
patients (195). Here, we demonstrate that the rare IgG4 isotype permeates lesions as well.  
Another unexpected feature of B lymphocytes in DCL is that they share markers 
with MZ B cells. This could explain their retention in lesions and the diffuse nature of the 
disease. Upregulation of MZB1 in DCL (500-fold) was unexpected in skin and we 
observed other transcriptional signatures common to MZ B cells in LCL and DCL, 
including an upregulation of complement receptors (CD1D, CD21, and CD35; data not 
shown) and CD27 (Figure 15A) and a lack of germinal center markers (BCL6, CD10; 
data not shown) (196–201). MZ B cells can respond to blood-borne thymus-independent 
(TI) antigens and help initiate APC uptake of antigen (200), produce excess antibody and 
cytokines, and act in antigen presentation and tissue repair (196, 202, 203). Schiller et al. 
discovered these cells in fibrotic skin and lung tissue, exposing their ability to contribute 
to disease (204). The recirculating tendencies of “memory”-like MZ B cells (197) could 
explain the phenotype of uncontrolled lesion development in later stages of DCL. It is 
well known that early immune responses to Leishmania sp. in murine infection help 
define important T cell activation states that eventually lead to control or susceptibility. 
The same could hold for B cells and an early and sustained atypical B cell response in 
these patients could contribute to the pathology and progression of this disease 
Immunoglobulin sequencing analysis indicating skewed usage of specific V genes 
in heavy and light chain immunoglobulins (Figure 17). Analysis of V-J combinations in 
DCL patients supports this theory, revealing a relatively restricted subset of gene usage, 
indicating the possibility of an oligoclonal response (Figure 16). Further analysis is 







selection processes within diffuse leishmaniasis lesions and the parasite antigens that 
drive this response.  
Along with the presence of atypical and active B cells in DCL lesions, we 
witnessed a change in the T cell population that could also equally contribute to parasite 
survival and disease progression. It is widely accepted that in murine models of 
leishmaniasis, a Th1 response is responsible for protection against Leishmania major, 
while a Th2 response leads to parasite persistence (75, 205). In DCL lesions, we observed 
an increase in transcripts for CD4 (~6-fold higher than healthy skin), a magnitude similar 
to that observed in LCL. However, further analysis of Th1 effectors and the transcription 
factor TBET (Figure 18) demonstrated a diminished Th1 response in DCL relative to 
LCL. This decreased Th1 response in DCL was not compensated for by an increased Th2 
response. Contradictory to previous works (94, 206), neither LCL nor DCL lesions 
exhibited any signs of a Th2 transcriptional response (Figure 18B, Figure 20). In fact 
transcripts for the canonical Th2 cytokines, IL-4, and IL-13 were virtually absent in DCL, 
indicating that the enhanced susceptibility in human DCL is not due to a Th2 immune 
response.  
The role of cytotoxic CD8+ T cells in leishmaniasis remains controversial (72). 
We observed an increase in CD8 transcripts of nearly 32-fold above uninfected skin in 
LCL, but in DCL these transcripts were only increased by 8-fold. This relative lack of 
CD8 transcripts in DCL correlated with a marked decrease in transcripts for perforin, 
granzymes, and granulysin (Figure 18C). We hypothesize that the paucity of CTLs in 
DCL may allow for prolonged survival of infected macrophages, thereby promoting 







transcripts mapping to the parasite genome observed in Figure 21 (207, 208). As for 
markers of anergy, expression was higher in the LCL compared to DCL environment, but 
without functional assays, we cannot attribute this to a particular subset of T cells. 
However, it does suggest that anergy does not contribute to the lack of cytotoxic effector 
molecules in DCL lesions. Thus, the commonly used designation of anergic DCL may 
need to be reconsidered.  
 In our previous work on LCL, we demonstrated host responses indicative of 
classically-activated macrophages, with substantial upregulation of IDO1, CXCL9, 
CXCL10, CXCL11, iNOS, IL-6, and TNF (179). We found that classical activation 
markers were significantly dampened in DCL lesions (Figure 19B). Due to the significant 
increases in immunoglobulin presence in lesions, we hypothesized that the regulatory 
macrophage phenotype would more likely exist. Indeed, our data found upregulation of 
anti-inflammatory and angiogenic gene transcription in DCL lesions (Figure 19C). 
Expression of MARCO on macrophages could also contribute to parasite persistence 
through retention of MZB1+ B cells (203, 209–211) and enhanced ERK1/2 signaling 
known to exacerbate disease (212, 213). This heightened presence of the anti-
inflammatory nature of regulatory macrophages supports increased parasite survival as 
intracellular pathogen killing is diminished in this macrophage subset (13).  
In-depth views into the parasite transcriptome in vivo revealed extensive 
information and allowed for identification of important parasite genes that could 
contribute to disease pathology. First and foremost, the uniformity among parasite 
transcription was quite remarkable (Figure 21) despite the differences in patient age (15-







transcriptome to in vitro macrophage infection with the same species (Figure 21C), we 
show that 75% of the genome is expressed at similar levels, while 25% of genes differ in 
expression between these infections. These differences demonstrate the need for further 
study of Leishmania infections within the lesion microenvironment as in vitro studies 
may not reveal the entire picture. 
More importantly, we combined our most recent data from DCL parasites with 
previous parasite transcriptome datasets to narrow the list of targets for disease causation. 
On the whole transcriptome scale, we noted that parasites in DCL lesions possess similar 
gene expression to the senescent and thriving population of parasites in macrophage 
infections in vitro (Figure 22A). We also identified a panel of 137 genes that are highly 
expressed regardless of disease manifestation and species (Figure 22C). Many of the 
proteins coded for by these genes have unknown structures and functions (Table 8), 
indicating the need for continued research and annotation of parasite genomes. These 
genes could serve as the basis for research in pan-Leishmania therapeutics and vaccines. 
Previous research has shown that the difference in manifestation of disease is due 
simply to changes in the host (214). More recent research has implicated specific parasite 
gene contributions to this phenomena (215–217). We identified L. amazonensis genes 
expressed at a higher level in DCL compared to other infections that could contribute to 
disease. This list should be a starting point for understanding the host-pathogen 
interactions and parasite manipulation of host responses.  
In conclusion, we used high-throughput sequencing to characterize the host 
immune response and parasite gene expression in human diffuse cutaneous leishmaniasis 







spread over most of a patient’s body. Our analysis of host transcriptomes demonstrated 
an expected reduction of inflammatory responses and signaled the existence of regulatory 
macrophages that are unable to kill parasites. We believe the DCL pathology is a result of 
improperly biased B cell responses that lead to dampened macrophage inflammation and 
is coupled with a lack of T cell cytotoxicity. The infiltration of atypical B cells and 
increased IgG4/IgG2 production demonstrate a possible role in shifting the immune 
response away from Th1 environments necessary for parasite killing and infection 
resolution. In macrophages, we observe augmented immunoregulatory and anti-
inflammatory responses coupled with angiogenesis, reorganization of extracellular 
matrix, and flourishing parasite growth. Furthermore, we cannot ignore possible parasite 
manipulation of the immune response and have identified parasite genes that may 
contribute to the diffuse nature of the disease. We also identified conserved parasite gene 
expression across multiple species and conditions. This knowledge is extremely 
important in understanding pathogen manipulation of the host and developing vaccines 
and therapeutics for this neglected tropical disease. Further research must be conducted to 







Chapter 5: Conclusions 
 
This work focused on characterizing the host and parasite transcriptomes in 
cutaneous leishmaniasis in an effort to further understand the host-pathogen interactions 
in this disease. We used the platform of RNA-seq to simultaneously analyze human and 
Leishmania transcripts in localized and diffuse manifestations of the disease, comparing 
and contrasting immune responses and parasite gene expression.  
In the first part of this study, we characterized the host transcriptome in localized 
cutaneous leishmaniasis. Unexpectedly, our analysis discovered host responses diverging 
based on the presence of actively transcribing parasites. Among the 25 localized 
cutaneous leishmaniasis patients, we observed three distinct transcriptomic populations 
based on parasite transcript presence. The differences in parasite reads was unexpected 
considering a previous study that used RNA-seq to compare L. braziliensis LCL and 
MCL manifestations (218). In that study, Maretti-Mira et al. found the percent of reads 
that mapped to the parasite genome was less than or equal to 0.25 percent. However, our 
study contained 25 total samples, five times the number of samples in the previous study.  
Using a larger sample set, we found six samples containing parasite transcripts 
(PTPos) whose host immune responses differed greatly from 10 samples containing no 
parasite transcripts (PTNeg). Transcriptomic differences included increased B cell 
infiltration and transcription of immunoglobulin. This response is paradoxical; increased 
leukocyte infiltration and activation should help control infection. However, these 
intracellular pathogens have harnessed the opsonization and subsequent phagocytosis 
pathway to gain entry into and manipulate their desired host macrophages. These findings 







presence of immunoglobulin increases susceptibility to Leishmania infections (60). Miles 
et al. demonstrated that even in mice with a healing Th1 response, irrelevant IgG 
presence exacerbated disease. It could be that an initial immunoglobulin response to 
either parasite antigen or sandfly antigen allowed parasite survival in the 6 PTPos patients. 
Regardless, we have expanded this observation to human localized cutaneous 
leishmaniasis. 
Markers of inflammation (IFNγ, TNF, GZMB, GLYN) and immune regulation 
(IL-10, CTLA4, PD-1, LAG3) also correlated well to parasite transcript presence. This 
displays the balance between inflammatory, inhibitory, and cytotoxic markers within this 
disease. If parasite persists in the lesion (PTPos), the immune response is to increase 
inflammatory cytokines and cytotoxic molecule secretion. These inflammatory cytokines 
should aid in parasite clearance. However, the increased inhibitory markers demonstrate 
the counterbalancing effect of IL-10 signaling to infected macrophages and inhibitory 
CTLA4, PD-1, and LAG3 signaling of T cell activation.  
Despite low parasite transcript numbers in 19 of 25 patients, we reported parasite 
transcriptome information in the 6 PTPos patients. We observed remarkable uniformity 
among parasite gene transcription despite varied disease progression (3 early and 3 late). 
We know that the immune response in these six samples does not vary despite the 
differences in infection duration and clinical classification. Hence, it is not surprising that 
the parasite gene expression displays such homogeneity. Combined with data from in 
vitro infections, we noted more than 150 highly expressed parasite genes regardless of 
species and infection environment. We also were able to identify more than 150 genes 







braziliensis. We controlled for parasite species differences by narrowing the analysis to 
single reciprocal orthologs based on the TriTrypDB database. While this eliminated some 
large gene or protein families, our analysis included 6707 genes or roughly 80% of L. 
braziliensis genes. 
Expansion of our analyses to include observations in diffuse cutaneous 
leishmaniasis proved notable as well. Using similar methods, we characterized the host 
transcriptome in diffuse cutaneous leishmaniasis. Similar to LCL, host responses appear 
to establish early on during infection and continue unchanged over time. Most notably, 
we identified increased atypical B cell transcript expression and immunoglobulin isotype 
switching to IgG4. The upregulation of B cell marker MZB1 was unexpected considering 
its canonical use as a marker for marginal zone, not peripheral, B cells. The recent 
discovery by Schiller et al. that revealed increased presence of MZB1+ B cells in tissue 
fibrosis increases our confidence that these cells contribute to DCL disease. The 
propensity for retention in the skin could contribute to excessive local immunoglobulin 
production, whereas recirculatory phenotypes could cause diffusion to other skin sites.  
Increased overall immunoglobulin production in DCL lesions that contain high 
numbers of parasites further substantiates our claims that immunoglobulin exacerbates 
disease. However, it seems that more is at play in diffuse lesions after observing a 
striking dominance of the rare IgG4 isotype. While other isotypes, such as IgG1 and 
IgG2, expressed at lower levels may contribute to parasite survival via opsonization and 
phagocytosis, the IgG4 isotype is known to create anti-inflammatory responses through 
competitive and inhibitory signaling. We believe the combination of these signals amount 







In DCL, lower levels of Th1 effectors IFNγ, TNF, and IL1β did not correlate to 
higher levels of Th2 effectors or markers. In fact, both LCL and DCL lacked evidence of 
a Th2 response known for predicting susceptibility and parasite survival in mouse 
models. Additionally, markers of T cell anergy were not upregulated in DCL compared to 
LCL. Analysis instead suggested that simply a reduced transcription of Th1 and cytotoxic 
effector molecules contribute to parasite survival in DCL lesions. The lack of a Th1 
dominant response limits the steps necessary for intracellular pathogen killing: 
macrophage activation and CTL activation.  
Further still, macrophage activation states contrasted sharply when comparing 
LCL and DCL. Markers of M1 “classically activated” macrophages were high in LCL 
and low in DCL, correlating well with presumed parasite killing. Positive markers of 
regulatory macrophages were evident in DCL, indicative of anti-inflammatory and 
angiogenic macrophage responses in a subset known to possess decreased intracellular 
parasite killing (13). Surprisingly, no evidence of alternatively activated macrophages 
was observed in LCL or DCL, suggesting that murine models implicating this subset of 
macrophage activation as contributing to susceptibility may not translate well into human 
systems.  
Analysis of the parasite transcriptome in diffuse lesions displayed a remarkable 
uniformity, regardless of the wide ranges in patient age and infection duration. This 
suggests that, similar to host responses, parasites gene expression does not change once 
infection is established in DCL. It appears that an equilibrium is reached where the host 








Comparisons to in vitro L. amazonensis demonstrated a similarity in 75% of the 
transcriptome. Roughly 10% of the difference in expression in ~1900 genes is accounted 
for by what we believe are genes that contribute to the manifestation of diffuse disease. 
The rest of the difference demonstrates the potential caveat of macrophage monolayer 
infections. Despite the lack of immune pressure in DCL disease, there appear to still be 
aspects of the lesion microenvironment that manifest in differences in parasite gene 
expression. Additional data from in vitro L. major parasite transcriptomes as well as our 
earlier analysis of the L. braziliensis transcriptome revealed a similar expression pattern 
between DCL and senescent in vitro macrophage infections, differing from LCL L. 
braziliensis. We curated lists of parasite genes that may contribute to DCL manifestations 
and parasite genes commonly expressed at a high level regardless of species, condition, 
or disease manifestation. Again, we corrected for differences in parasite species by only 
analyzing ~6700 genes that are single reciprocal orthologs. Despite this caveat, these 
informative subsets must be integral to Leishmania infection and contain potential targets 
for therapeutics and vaccines.  







Chapter 6: Future Directions 
 Continued research in the area of leishmaniasis based on this work includes future 
analyses at the RNA and protein levels of the host and parasite. These studies improve 
our knowledge of the interactions between host and pathogen and uncover contributors to 
disease manifestation, altered host responses, parasite virulence, and parasite survival. 
However, limitations based on sample availability, rarity, and special differences existed. 
Certain additions to the data could strengthen our conclusions.  
At the inception of this project, the biopsies acquired did not include healthy skin 
from the endemic region. The contribution of host genetic background is believed to be 
minimal considering travelers to endemic regions are also susceptible to infection. 
However, minimizing variables increases the confidence of conclusions. Our samples did 
not include paired biopsies from contralateral or “healthy” skin of infected patients. In 
murine models, previous research has demonstrated the presence of Leishmania-specific 
T cells in contralateral areas of infected mice (169, 219). The leukocytes in non-lesion 
areas of the skin may not be actively participating in cell-mediated immunity but seem to 
be poised to do so for the purpose of immune memory. While the addition of these 
biopsies would differentiate between pathological and nonpathological areas of the skin, 
our goal was to look at differences between healthy and infected skin as well as any 
differences within lesions. However, the addition of endemic area healthy and 
contralateral skin biopsies would give a clearer view of the interactions occurring within 
lesions. 
While our findings on transcriptomic differences in LCL and DCL lesions prove 







certainly strengthen our conclusions. Post-translational manipulations occur and 
confirmation of protein expression would confirm our hypotheses regarding causative 
factors within and between each disease. However, sample acquisition is difficult in these 
endemic areas, limiting follow-up studies. Additionally, the rarity of DCL disease limits 
study. 
Our assessment of two disease manifestations caused by two different parasites 
begs the question of whether or not the comparison is legitimate. We believe that despite 
this difference, we are still able to compare host responses that reside at opposite ends of 
the leishmaniasis disease spectrum. Our discovery notes that myriad factors contribute to 
the spectral nature of the disease and we have begun to characterize such factors. 
However, further RNA-seq studies would increase the robustness of our conclusions. 
Additional biopsies from L. amazonensis-infected localized cutaneous leishmaniasis 
would allow for direct comparisons of in vitro macrophage infection alongside in vivo 
LCL and DCL. While this would eliminate the difference in parasite species, we would 
expect the L. amazonensis-infected LCL lesions to exhibit characteristics more similar to 
DCL than to L. braziliensis-infected LCL. We hypothesize this because L. amazonensis-
infected LCL lesions contain higher levels of parasite than L. braziliensis infection due to 
differences in cellular localization of parasite. Within the macrophage, a phagolysosome 
can contain multiple L. amazonensis parasites, whereas each phagolysosome in L. 
braziliensis infection contains just one parasite.  Regardless, this would narrow the lists 
of genes and pathways responsible in diverging host responses.  
In order to further study the differences between in vitro macrophage infections 







already analyzed in vitro infections. In the same manner, we could compare L. 
braziliensis macrophage infections in vitro to already analyzed lesion data. This would 
help to test our hypothesis of differing parasite expression in lesion microenvironments 
(immune pressure) versus in vitro macrophage infections. Additional in vitro experiments 
using IFN-γ primed macrophages may show a higher degree of similarity in parasite gene 
expression to LCL lesions. All of these assessments within each parasite transcriptome 
would eliminate the caveat of multiple species comparisons and identify parasite genes 
responding to immune pressure and affecting differing manifestations. 
Genomic differences in the host and parasite must also be assessed to ensure that 
(1) host genomic differences do not contribute to differences in disease manifestation or 
susceptibility and (2) the L. amazonensis parasite that causes LCL and DCL are the same. 
Analysis of SNPs may be able to confirm or reject the hypothesis regarding host and 
parasite differences.  
 Most importantly, the identified highly expressed parasite genes should be 
screened for contributions to virulence and survival. Because many of these genes code 
for hypothetical proteins, assays to determine structure, protein-protein interactions, and 
any contributions to virulence or survival must be completed. With this knowledge, 
targeted therapies could interfere with specific parasite genes or pathways, opening the 
door for pan-Leishmania therapeutics that could improve patient quality of life. The same 
data would also unveil new targets for vaccines that could be applied for multiple 
Leishmania species, decreasing medical costs and minimizing prevalence of this 
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